SEARCH
検索詳細
今福 恵輔 (イマフク ケイスケ)
| 北海道大学病院 脳・神経・感覚器科 | 助教 |
研究者基本情報
■ 学位■ URL
researchmap URLホームページURL■ ID 各種
研究者番号
- 80963470
研究キーワード研究分野
研究活動情報
■ 論文- Erlotinib impairs epidermal tight junction and barrier integrity by inhibiting EGFR and Src and affects maturation of cell–cell junctions in human and mouse keratinocytes
Keisuke Imafuku; Alexander Garcia-Ponce; Jens Waschke
Tissue Barriers, 2696758, 2696758, 2026年07月13日, [国際誌]
英語, 研究論文(学術雑誌), Erlotinib, an epidermal growth factor receptor (EGFR) inhibitor, is widely used in cancer therapy but frequently causes cutaneous adverse effects that suggest impairment of the epidermal barrier. To better understand the underlying mechanisms, we examined how erlotinib affects barrier integrity, with a focus on tight junctions (TJs) and their relation with the actin cytoskeleton. Using human and mouse ex vivo epidermis as well as cultured keratinocytes, we assessed junctional assembly and stability under pharmacological inhibition of EGFR and Src. Erlotinib treatment disrupted the epithelial barrier, as demonstrated by enhanced biotin tracer penetration and a marked reduction in transepithelial electrical resistance. In line with functional impairment, erlotinib reduced EGFR and Src activity disturbing maturation of junctions, as evidenced by discontinuous claudin-1 and ZO-1 localization. Furthermore, erlotinib induced a loss of the apically localized tension-sensitive conformation of α-catenin in the stratum granulosum and in cultured keratinocytes. This was accompanied by disorganization of cortical actin and increased presence of stress fibers, in parallel with elevated activation of RhoA and phosphorylation of MLC2. Inhibition of Src with PP2 led to similar effects on barrier integrity. However, this detrimental outcome could be rescued by EGF treatment. Together, these findings indicate that erlotinib impairs epidermal barrier function by affecting junctional maturation via disrupted α-catenin membrane distribution, and ultimately, TJ stability involving intracellular contraction and tension. Thus, strategies focused on targeting tension‑related mechanisms downstream of EGFR/Src might help prevent or alleviate the cutaneous toxicities associated with EGFR inhibitory therapies. - mTOR-Responsive PIK3CA p.E542K-Harboring Sweat Gland Carcinoma With Neuroendocrine Differentiation.
Soma Sato; Keisuke Imafuku; Shin Ariga; Hideyuki Ujiie
International journal of dermatology, 2026年06月26日, [国際誌]
英語 - A Growing Dark Mass in a Patient With a History of Trauma
Takahiro Hase; Keisuke Imafuku; Teruki Yanagi; Arisa Tanaka; Ayame Kimura; Suguru Kurosawa; Takashi Seo; Hideyuki Ujiie
JEADV Clinical Practice, 2026年06月03日
研究論文(学術雑誌) - Spontaneous regression of Merkel cell carcinoma: A case report with pathological and genetic analyses
S. Hikichi; T. Yanagi; S. Kitamura; H. Nishihara; K. Miyamoto; S. Mai; K. Tokuchi; T. Maeda; K. Imafuku; H. Ujiie
The Journal of Dermatology, 2025年04月
研究論文(学術雑誌) - SpO2低下により診断し得たジアフェニルスルホンによるメトヘモグロビン血症の2例
黒澤 卓; 宮澤 元; 渡邉 美佳; 長田 悠里; 眞井 翔子; 得地 景子; 今福 恵輔; 氏家 英之; 木村 彩萌; 伊藤 圭
日本皮膚科学会雑誌, 134, 6, 1657, 1657, (公社)日本皮膚科学会, 2024年05月
日本語 - Native collagen XVII complex ELISA: An approach for diagnosis and monitoring of anti‐integrin β4 mucous membrane pemphigoid
S. Mai; K. Izumi; S. Itamoto; S. Kurosawa; Y. Nagata; S. Hikichi; H. Miyazawa; K. Tokuchi; K. Imafuku; T. Yanagi; M. Tsutsui; H. Ujiie
Journal of the European Academy of Dermatology and Venereology, 2024年05月
研究論文(学術雑誌) - エルロチニブとラムシルマブの併用療法中に穿孔性皮膚症と紫斑,皮膚潰瘍を生じた1例
森田 裕介; 今福 恵輔; 板本 想太; 挽地 史織; 眞井 翔子; 宮澤 元; 得地 景子; 榊原 純; 氏家 英之
臨床皮膚科, 78, 2, 119, 124, (株)医学書院, 2024年02月
日本語 - 慢性骨髄単球性白血病に合併した尋常性天疱瘡の1例
三浦 譲司; 眞井 洋輔; 成瀬 早紀; 澁佐 知歩; 島野 麻由奈; 野原 拓馬; 挽地 史織; 小住 英之; 長田 悠理; 黒澤 卓; 眞井 翔子; 宮澤 元; 得地 景子; 渡邉 美佳; 今福 恵輔; 片山 奨; 氏家 韻欣; 泉 健太郎; 氏家 英之; 宮澤 仁; 遠藤 知之
日本皮膚科学会雑誌, 133, 12, 2854, 2854, (公社)日本皮膚科学会, 2023年11月
日本語 - Hand‐foot syndrome histopathologically presenting eccrine squamous syringometaplasia due to pembrolizumab after lenvatinib treatment
Sota Itamoto; Keisuke Imafuku; Hajime Miyazawa; Takashi Anan; Hiroko Matsumiya; Daisuke Endo; Takashi Mitamura; Hideyuki Ujiie
Journal of Cutaneous Pathology, 50, 11, 932, 935, 2023年11月, [国際誌]
英語, 研究論文(学術雑誌) - 水疱性類天疱瘡とBullous Rheumatoid Neutrophilic Dermatosisとの鑑別を要したリウマトイド血管炎
田中 有沙; 柳 輝希; 今福 恵輔; 渥美 達也; 氏家 英之
皮膚科の臨床, 65, 10, 1531, 1534, 金原出版(株), 2023年09月
日本語 - 抗真菌薬外用により急速に上皮化した難治性うっ滞性皮膚潰瘍の1例
澁佐 知歩; 宮澤 元; 渡邉 美佳; 黒澤 卓; 長田 悠里; 眞井 翔子; 得地 景子; 今福 恵輔; 高島 翔太; 氏家 英之; 細川 一義
日本皮膚科学会雑誌, 133, 9, 2183, 2183, (公社)日本皮膚科学会, 2023年08月
日本語 - Cutaneous chronic expanding hematoma on the elbow mimicking a malignant tumor: report of a case and review of the literature
Hase T; Imafuku K
2023年07月
研究論文(学術雑誌) - Pseudotumor of the skin due to Mycobacterium genavense.
Suguru Kurosawa; Keisuke Imafuku; Sho Nakakubo; Sumio Iwasaki; Takanori Teshima; Hideki Goto; Hideyuki Ujiie
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 134, 88, 90, 2023年05月15日, [国際誌]
英語, 研究論文(学術雑誌), Mycobacterium genavense is a rare type of non-tuberculous mycobacterium (NTM) that has been reported to cause disseminated infections in immunocompromised patients. Because M. genavense is slow-growing and poorly able to form colonies on Ogawa's medium, genetic and molecular analyses are necessary to identify this pathogen. NTM infections present with various cutaneous manifestations. Of these, rare cases have been reported to present with mycobacterial pseudotumors. However, there are no reports of M. genavense with cutaneous pseudotumors. In this paper, we report a case of a pseudotumor due to M. genavense infection that was observed only in a cutaneous lesion. The patient was taking 5 mg of prednisolone and was aware of a tumor on the right lower leg. Biopsy samples showed diffuse spindle-shaped histiocytes and various other inflammatory cell infiltrates, and Ziehl-Neelsen staining detected mycobacterium. Since no colonies formed on Ogawa medium, genetic testing was performed, and M. genavense was identified by DNA sequence analysis. There were no other disseminated lesions beyond the skin, including in the lungs and liver. Since the patient was immunosuppressed, in accordance with previous literature, a combination therapy of clarithromycin, ethambutol, and rifampicin for 4 months was recommended. When no growth is observed on Ogawa's medium in cases of infection, it is essential to identify the infectious pathogen by genetic analysis. - 当科におけるポリヘキサニド・ベタイン溶液を用いた局所療法の使用経験
須貝 達朗; 今福 恵輔; 板本 想太; 挽地 史織; 黒澤 卓; 長田 悠里; 葭本 倫大; 森田 裕介; 氏家 英之
日本皮膚科学会雑誌, 133, 5, 1403, 1403, (公社)日本皮膚科学会, 2023年05月
日本語 - エルロチニブ(EGFRチロシンキナーゼ阻害薬)により生じた血管炎の1例
挽地 史織; 宮澤 元; 板本 想太; 眞井 翔子; 得地 景子; 今福 恵輔; 榊原 純; 氏家 英之
日本臨床皮膚科医会雑誌, 40, 3, 466, 466, 日本臨床皮膚科医会, 2023年05月
日本語 - 基底膜タンパク複合体を利用したELISAで診断し得た粘膜類天疱瘡の1例
眞井 翔子; 泉 健太郎; 板本 想太; 黒澤 卓; 長田 悠里; 挽地 史織; 宮澤 元; 得地 景子; 今福 恵輔; 柳 輝希; 筒井 眞人; 氏家 英之
日本臨床皮膚科医会雑誌, 40, 3, 477, 477, 日本臨床皮膚科医会, 2023年05月
日本語 - Mycobacterium genavenseによる限局性の皮膚感染症を呈した1例
黒澤 卓; 今福 恵輔; 宮澤 元; 中久保 祥; 岩崎 澄央; 後藤 秀樹; 豊嶋 崇徳; 氏家 英之
日本臨床皮膚科医会雑誌, 40, 3, 470, 470, 日本臨床皮膚科医会, 2023年05月
日本語 - 右耳介後部の結節
中里 信一; 外丸 詩野; 清水 亜衣; 高桑 恵美; 大塚 紀幸; 前田 拓哉; 今福 恵輔; 阿南 隆; 氏家 英之; 松野 吉宏
日本皮膚病理組織学会抄録集, 39回, 40,22, 40,22, 日本皮膚病理組織学会, 2023年04月
日本語 - Zonula occludens‐1 distribution and barrier functions are affected by epithelial proliferation and turnover rates
Keisuke Imafuku; Hiroaki Iwata; Ken Natsuga; Makoto Okumura; Yasuaki Kobayashi; Hiroyuki Kitahata; Akiharu Kubo; Masaharu Nagayama; Hideyuki Ujiie
Cell Proliferation, 56, 9, e13441, Wiley, 2023年03月14日, [国際誌]
英語, 研究論文(学術雑誌), Zonula occludens-1 (ZO-1) is a scaffolding protein of tight junctions, which seal adjacent epithelial cells, that is also expressed in adherens junctions. The distribution pattern of ZO-1 differs among stratified squamous epithelia, including that between skin and oral buccal mucosa. However, the causes for this difference, and the mechanisms underlying ZO-1 spatial regulation, have yet to be elucidated. In this study, we showed that epithelial turnover and proliferation are associated with ZO-1 distribution in squamous epithelia. We tried to verify the regulation of ZO-1 by comparing normal skin and psoriasis, known as inflammatory skin disease with rapid turnover. We as well compared buccal mucosa and oral lichen planus, known as an inflammatory oral disease with a longer turnover interval. The imiquimod (IMQ) mouse model, often used as a psoriasis model, can promote cell proliferation. On the contrary, we peritoneally injected mice mitomycin C, which reduces cell proliferation. We examined whether IMQ and mitomycin C cause changes in the distribution and appearance of ZO-1. Human samples and mouse pharmacological models revealed that slower epithelial turnover/proliferation led to the confinement of ZO-1 to the uppermost part of squamous epithelia. In contrast, ZO-1 was widely distributed under conditions of faster cell turnover/proliferation. Cell culture experiments and mathematical modelling corroborated these ZO-1 distribution patterns. These findings demonstrate that ZO-1 distribution is affected by epithelial cell dynamics. - ポリヘキサニド・ベタイン溶液を用いた局所療法が奏効した下腿潰瘍の2例
須貝 達朗; 今福 恵輔; 板本 想太; 挽地 史織; 葭本 倫大; 森田 裕介; 氏家 英之
日本皮膚科学会雑誌, 133, 3, 540, 540, (公社)日本皮膚科学会, 2023年03月
日本語 - エルロチニブ(EGFR阻害薬)により発症した薬剤性皮膚潰瘍の1例
挽地 史織; 宮澤 元; 板本 想太; 眞井 翔子; 得地 景子; 今福 恵輔; 氏家 英之; 榊原 純
日本皮膚科学会雑誌, 133, 3, 540, 540, (公社)日本皮膚科学会, 2023年03月
日本語 - 当院における乾癬性ぶどう膜炎4例のまとめ
宮澤 元; 夏賀 健; 今福 恵輔; 氏家 英之; 南場 研一
日本皮膚科学会雑誌, 133, 2, 273, 273, (公社)日本皮膚科学会, 2023年02月
日本語 - Annular leukocytoclastic vasculitisの1例
長田 悠里; 宮澤 元; 板本 想太; 挽地 史織; 眞井 翔子; 今福 恵輔; 得地 景子; 泉 健太郎; 氏家 英之
日本皮膚科学会雑誌, 133, 2, 274, 274, (公社)日本皮膚科学会, 2023年02月
日本語 - Multiple courses of steroid pulse therapy are required in treating acquired idiopathic generalized anhidrosis patients with a large anhidrotic area: A retrospective study of 28 cases
Imafuku K; Yanagi T; Yoshimoto N; Miyazawa H; Iwata H; Ujiie H
Australasian Journal of Dermatology, 65, 1, 55, 58, 2023年01月, [国際誌]
英語, 研究論文(学術雑誌), Patients with acquired idiopathic generalized anhidrosis (AIGA) demonstrate a sudden loss of sweating function without neurological or endocrine abnormalities. The main treatment is steroid pulse therapy. However, the number of courses required for improvement has been unclear. This study aims to clarify the factors associated with AIGA disease severity and with AIGA patients' responses to steroid pulse therapy. We retrospectively analysed the clinical information of 28 patients with AIGA in our department from the last 10 years. Univariate analysis revealed that patients with a large anhidrotic area need multiple courses of steroid pulse therapy. - 基底膜部にIgM抗体の沈着を認めた表皮下水疱症の1例
平野 瑶子; 岩田 浩明; 辻脇 真澄; 眞井 翔子; 眞井 洋輔; 今福 恵輔; 泉 健太郎; 氏家 英之; 古賀 浩嗣
日本皮膚科学会雑誌, 132, 12, 2696, 2696, (公社)日本皮膚科学会, 2022年11月
日本語 - 治療に難渋したペムブロリズマブによる中毒性表皮壊死症の1例
長田 悠里; 葭本 倫大; 黒澤 卓; 瀬尾 拓志; 須貝 達朗; 森田 裕介; 今福 恵輔; 氏家 韻欣; 氏家 英之; 山村 貴洋
日本皮膚科学会雑誌, 132, 12, 2705, 2705, (公社)日本皮膚科学会, 2022年11月
日本語 - 壊疽性膿皮症が疑われた壊疽性膿瘡の2例
田中 有沙; 柳 輝希; 小川 弘記; 瀬尾 拓志; 小住 英之; 眞井 翔子; 宮澤 元; 今福 恵輔; 夏賀 健; 氏家 英之; 箱崎 茉衣
日本皮膚科学会雑誌, 132, 12, 2697, 2698, (公社)日本皮膚科学会, 2022年11月
日本語 - 悪性黒色腫の診療ガイドライン
中村 泰大; 浅井 純; 井垣 浩; 猪爪 隆史; 並川 健二郎; 林 礼人; 福島 聡; 藤村 卓; 伊東 孝通; 今福 惠輔; 田中 亮多; 寺本 由紀子; 皆川 茜; 宮川 卓也; 宮下 梓; 和田 誠
皮膚科, 2, 1, 134, 142, (有)科学評論社, 2022年07月
日本語 - 当科でパルス療法を施行した特発性後天性全身性無汗症患者の解析
今福 恵輔; 柳 輝希; 葭本 倫大; 宮澤 元; 岩田 浩明; 氏家 英之
日本皮膚科学会雑誌, 132, 5, 1307, 1307, (公社)日本皮膚科学会, 2022年05月
日本語 - Super-resolution imaging detects BP180 autoantigen in immunoglobulin M pemphigoid.
Yoko Hirano; Hiroaki Iwata; Masumi Tsujuwaki; Shoko Mai; Yosuke Mai; Keisuke Imafuku; Kentaro Izumi; Hiroshi Koga; Hideyuki Ujiie
The Journal of dermatology, 49, 3, 374, 378, 2022年03月, [国際誌]
英語, 研究論文(学術雑誌), Bullous pemphigoid is generally caused by immunoglobulin (Ig)G autoantibodies against hemidesmosomal BP180 and/or BP230. Recently, the concept of IgM pemphigoid has been proposed. A 23-year-old Japanese woman presented with a 4-month history of severely itchy papules showing subepidermal separations with mild neutrophil infiltration. Direct immunofluorescence (DIF) revealed IgM deposits at the dermoepidermal junction, but neither IgG nor IgA deposits. Indirect immunofluorescence on 1 M NaCl-split skin demonstrated deposits on the epidermal side. The optical density (OD) value of a modified IgM enzyme-linked immunosorbent assay for full-length BP180, but not for BP180-NC16A, was increased. The patient was diagnosed with IgM pemphigoid and was treated with diphenyl sulfone at 50 mg/day without recurrence. To confirm the precise autoantigen, we tried to obtain super-resolution imaging. The deposition pattern of IgM autoantibodies seemed to be oriented parallel to that of BP180. The detailed images detect DIF deposits apart from BP180-NC16A staining, but are close to type VII collagen-NC1 staining. This result suggests that the IgM autoantibodies in the patient might target the C-terminus of BP180. IgM pemphigoid is still not a widely accepted concept, and the clinical course remains unknown. We will carefully follow-up the patient. Super-resolution images may help to detect precise autoantigens in autoimmune blistering diseases. - Safety and dose-sparing effect of Japanese encephalitis vaccine administered by microneedle patch in uninfected, healthy adults (MNA-J): a randomised, partly blinded, active-controlled, phase 1 trial.
Hiroaki Iwata; Kosuke Kakita; Keisuke Imafuku; Shota Takashima; Naoya Haga; Yasuyuki Yamaguchi; Kenji Taguchi; Takayoshi Oyamada
The Lancet. Microbe, 3, 2, e96-e104, 2022年02月, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: It is unclear whether microneedle vaccinations of Japanese encephalitis virus can induce sufficient neutralising antibodies and reduce the amount of vaccine needed. We aimed to assess the safety and dose-sparing effect of a microneedle vaccine patch against Japanese encephalitis in healthy individuals who are naive to both the vaccine and natural infection. METHODS: The MNA-J study was a randomised, partly blinded, active-controlled, phase 1 clinical trial at Hokkaido University (Sapporo, Japan) that enrolled healthy adults aged 20-34 years with no history of Japanese encephalitis vaccination nor of infection as confirmed by seronegativity. We excluded individuals who had been infected with or vaccinated against Japanese encephalitis. Eligible participants were randomly assigned (1:1:1) to one of three groups to receive inactivated Japanese encephalitis vaccine administered twice, 3 weeks apart, by either 2·5 μg per injection by subcutaneous injection, 0·63 μg per patch by high-dose microneedle array (MNA-25%), or 0·25 μg per patch by low-dose microneedle array (MNA-10%). The randomisation sequence, using stratification by cohort and blocks of six, was computer-generated by a statistician who was unaware of group assignment. After administration, the remaining amount of unadministered vaccine was measured by ELISA and calculated as the delivered amount of vaccine. The primary outcome was the neutralising antibody titre at day 42 after first immunisation. Successful seroconversion was defined as post-vaccination titres of 1·3 (log10) or higher in individuals whose pre-vaccination titres had been less than 1 (log10). This study is registered with the Japan Registry of Clinical Trials (s011190004). FINDINGS: Between Aug 31 and Sept 2, 2019, 39 participants were enrolled and each was randomly assigned to a group (n=13 per group). No serious adverse events were observed. All participants in the microneedle array groups had a localised erythematous reaction. The amount of vaccine delivered by microneedle array to each participant was 0·63-1·15 μg (50-92%) of the full 1·26 μg for the MNA-25% group and 0·25-0·41 μg (51-84%) of the full 0·50 μg for the MNA-10% group. All participants demonstrated seroconversion at day 42, and the mean titres (log10) were 2·55 for MNA-25%, 2·04 for MNA-10%, and 2·08 for subcutaneous injection. INTERPRETATION: A microneedle patch of the Japanese encephalitis vaccine is safe, well tolerated, and immunogenically effective. The dose-sparing effect suggests a significant potential to reduce the amount of immunogens needed. However, improved delivery is needed to make it more tolerable and user friendly. FUNDING: FUJIFILM. - Macrolide/fluoroquinolone-resistant Campylobacter jejuni-induced cellulitis in a patient with X-linked agammaglobulinaemia successfully treated with carbapenem.
Joohyung Youh; Keisuke Imafuku; Teruki Yanagi; Sho Nakakubo; Yosuke Mai; Hideyuki Kosumi; Takuya Kawamura; Ken Muramatsu; Chihiro Shiiya; Ayame Kimura; Sota Itamoto; Masafumi Yamada; Hideyuki Ujiie
Dermatologic therapy, 34, 6, e15176, 2021年11月, [国際誌]
英語 - X連鎖無γグロブリン血症患者に発症した多剤耐性Campylobacter jejuniによる蜂窩織炎の1例
劉 柱亨; 柳 輝希; 板本 想太; 木村 彩萌; 眞井 洋輔; 村松 憲; 今福 恵輔; 氏家 英之; 中久保 祥; 山田 雅文
日本皮膚科学会雑誌, 131, 9, 2072, 2072, (公社)日本皮膚科学会, 2021年08月
日本語 - Zonula occludens-1 demonstrates a unique appearance in buccal mucosa over several layers.
Keisuke Imafuku; Mayumi Kamaguchi; Ken Natsuga; Hideki Nakamura; Hiroshi Shimizu; Hiroaki Iwata
Cell and tissue research, 384, 3, 691, 702, 2021年06月, [国際誌]
英語, 研究論文(学術雑誌), Tight junctions (TJs) firmly seal epithelial cells and are key players in the epithelial barrier. TJs consist of several proteins, including those of the transmembrane claudin family and the scaffold zonula occludens (ZO) family. Epithelial tissues are exposed to different conditions: to air in the stratified epithelium of the skin and to liquids in the monolayer of the intestine. The TJs in stratified oral mucosal epithelium have remained insufficiently elucidated in terms of distributions, appearances and barrier functions of TJ proteins in normal buccal mucosa. We investigated these and ZO-1 and claudin-1 were found to be expressed in the top third and in the bottom three quarters of the mucosal epithelium. ZO-1 in the buccal mucosa was found to have an irregular linear appearance. ZO-1 in the buccal mucosa continuously existed in several layers. Electron microscopy revealed the buccal mucosa to have kissing points. In a biotin permeation assay that sought to investigate inside-outside barrier function, the biotin tracer penetrated several ZO-1 layers but did not pass through all the ZO-1 layers. We found that the oral mucosal cell knockdown of TJP1 or CLDN1 resulted in decreases of TER but no significant change in FITC-dextran leakage. Our results suggest that the distribution and appearance of ZO-1 in the buccal mucosa differ from those in the skin. We were unable to prove barrier function in this study but we did show barrier function against small molecules in vivo and against ions in vitro. - 日本脳炎マイクロニードルワクチンによる用量低減効果
岩田 浩明; 今福 恵輔; 高島 翔太; 羽賀 直哉; 山口 泰之; 柿田 浩輔; 田口 賢治; 小山田 孝嘉
日本皮膚科学会雑誌, 131, 5, 1381, 1381, (公社)日本皮膚科学会, 2021年05月
日本語 - Loss of dynamin-related protein 1 (Drp1) does not affect epidermal development or UVB-induced apoptosis but does accelerate UVB-induced carcinogenesis.
Teruki Yanagi; Shinya Kitamura; Keisuke Imafuku; Asuka Suto; Takuya Maeda; Shinya Tanaka; Hiromi Sesaki; Riichiro Abe; Hiroshi Shimizu
Journal of dermatological science, 99, 2, 109, 118, 2020年08月, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: Mitochondrial morphology is controlled by fission and fusion. Dynamin-related protein 1 (Drp1, dynamin-1-like protein (Dnml1)) regulates mitochondrial fission, which is associated with cell division and apoptosis. We previously reported that DRP1 is indispensable for cell growth in cutaneous squamous cell carcinoma. However, little is known about Drp1 in normal epidermis/keratinocytes. OBJECTIVES: We investigated the function of Drp1 in normal epidermis/keratinocytes. METHODS: Epidermis-specific Drp1 knockout (EKO) mice were analyzed. RESULTS: Epidermal development in the EKO mice were indistinguishable from those in the wild-type (WT) mice. Ultrastructural analysis and immunohistochemistry revealed that the mitochondria of keratinocytes in the EKO mice were neither elongated nor constricted. Drp1 knockdown did not diminish the cell growth of normal human keratinocytes. Both in vivo and in vitro, UVB-induced apoptosis in the EKO epidermis and keratinocytes did not differ from that in the WT mice. In chronic UVB-irradiation, the loss of Drp1 sensitized the epidermis to the development of skin tumors. Clinically, DRP1 is expressed more highly in sun-exposed skin than in non-exposed skin in individuals under age 40, but not in those over age 60. CONCLUSION: EKO mice demonstrate that Drp1 is dispensable for the development and apoptosis of the epidermis. Drp1 plays critical roles in malignant tumors; thus, the molecular machinery of mitochondrial dynamics involving Drp1 could be a novel therapeutic target for malignant keratinocytic lesions. On the other hand, the anti-tumorigenic role of Drp1 in chronic UVB-induced carcinogenesis need to be further investigated. - Japanese Dermatological Association Guidelines: Outlines of guidelines for cutaneous melanoma 2019.
Yasuhiro Nakamura; Jun Asai; Hiroshi Igaki; Takashi Inozume; Kenjiro Namikawa; Ayato Hayashi; Satoshi Fukushima; Taku Fujimura; Takamichi Ito; Keisuke Imafuku; Ryota Tanaka; Yukiko Teramoto; Akane Minagawa; Takuya Miyagawa; Azusa Miyashita; Makoto Wada; Hiroshi Koga; Makoto Sugaya
The Journal of dermatology, 47, 2, 89, 103, 2020年02月, [国際誌]
英語, 研究論文(学術雑誌), With consideration of the ongoing developments in treatment options for cutaneous melanoma, the Japanese Skin Cancer Society published the first guidelines for cutaneous melanoma in 2007 and later revised them in 2015. Here, we report on an English version of the 2019 Japanese Melanoma Guidelines. In this latest edition, all processes were carried out according to the Grading of Recommendations, Assessment, Development and Evaluation system. A comprehensive published work search, systematic review and determination of recommendations in each clinical question were performed by a multidisciplinary expert panel consisting of dermatologists, a plastic and reconstructive surgeon, and a radiation oncologist. The advent of novel agents, such as immune checkpoint inhibitors and molecular-targeted agents, has drastically changed the nature of treatment for adjuvant and advanced-stage diseases among melanoma patients worldwide. Additionally, recent reports of clinical trials regarding surgical procedures and a better understanding of molecular biology and tumor immunology in clinical types of melanoma have had an impact on clinical practise. Based on these viewpoints, eight relevant clinical questions were raised in this report that aim to help clinicians select the appropriate therapeutic approach. - Evaluation of pazopanib cytotoxicity to normal vascular endothelial cells in vitro: A comment on Goto et al.
Shinya Kitamura; Teruki Yanagi; Takuya Maeda; Keisuke Imafuku; Hiroo Hata; Mikio Masuzawa; Hiroshi Shimizu
The Journal of dermatology, 46, 9, e341-e342, 2019年09月, [国際誌]
英語 - 日本皮膚科学会ガイドライン 皮膚悪性腫瘍ガイドライン第3版 メラノーマ診療ガイドライン2019
中村 泰大; 浅井 純; 井垣 浩; 猪爪 隆史; 並川 健二郎; 林 礼人; 福島 聡; 藤村 卓; 伊東 孝通; 今福 惠輔; 田中 亮多; 寺本 由紀子; 皆川 茜; 宮川 卓也; 宮下 梓; 和田 誠; 古賀 弘志; 菅谷 誠; 公益社団法人日本皮膚科学会, 一般社団法人日本皮膚悪性腫瘍学会, 皮膚悪性腫瘍診療ガイドライン改訂委員会(メラノーマ診療ガイドライングループ)
日本皮膚科学会雑誌, 129, 9, 1759, 1843, (公社)日本皮膚科学会, 2019年08月, [査読有り]
日本語 - CDK16/PCTK1/PCTAIRE1 is highly expressed in melanomas but not in melanocytic nevi or sarcomas.
Teruki Yanagi; Keisuke Imafuku; Shinya Kitamura; Hiroo Hata; Hiroshi Shimizu
The Journal of dermatology, 46, 7, 634, 636, 2019年07月, [国際誌]
英語, 研究論文(学術雑誌) - メルケル細胞癌におけるPET-CTのFDG集積に関する細胞学的検討
北村 真也; 柳 輝希; 高島 有香; 今福 恵輔; 秦 洋郎; 清水 宏; 平田 健司; 上原 治朗; 石田 雄大; 大塚 篤司
日本皮膚科学会雑誌, 129, 3, 353, 353, (公社)日本皮膚科学会, 2019年03月
日本語 - 扁平上皮におけるTripartite motif-containing protein 29(TRIM29)の機能解析
柳 輝希; 秦 洋郎; 北村 真也; 今福 恵輔; 清水 宏; 柳 紘子; 本間 明宏; 渡部 昌; 畠山 鎮次
日本皮膚科学会雑誌, 129, 1, 45, 45, (公社)日本皮膚科学会, 2019年01月
日本語 - リポフスチンはアポクリン汗嚢腫の色調に関連する
北村 真也; 柳 輝希; 今福 恵輔; 秦 洋郎; 清水 宏
日本皮膚科学会雑誌, 129, 1, 47, 47, (公社)日本皮膚科学会, 2019年01月
日本語 - Loss of TRIM29 Alters Keratin Distribution to Promote Cell Invasion in Squamous Cell Carcinoma.
Teruki Yanagi; Masashi Watanabe; Hiroo Hata; Shinya Kitamura; Keisuke Imafuku; Hiroko Yanagi; Akihiro Homma; Lei Wang; Hidehisa Takahashi; Hiroshi Shimizu; Shigetsugu Hatakeyama
Cancer research, 78, 24, 6795, 6806, 2018年12月15日, [国際誌]
英語, 研究論文(学術雑誌), : TRIM29 (tripartite motif-containing protein 29) is a TRIM family protein that has been implicated in breast, colorectal, and pancreatic cancers. However, its role in stratified squamous epithelial cells and tumors has not been elucidated. Here, we investigate the expression of TRIM29 in cutaneous head and neck squamous cell carcinomas (SCC) and its functions in the tumorigenesis of such cancers. TRIM29 expression was lower in malignant SCC lesions than in adjacent normal epithelial tissue or benign tumors. Lower expression of TRIM29 was associated with higher SCC invasiveness. Primary tumors of cutaneous SCC showed aberrant hypermethylation of TRIM29. Depletion of TRIM29 increased cancer cell migration and invasion; conversely, overexpression of TRIM29 suppressed these. Comprehensive proteomics and immunoprecipitation analyses identified keratins and keratin-interacting protein FAM83H as TRIM29 interactors. Knockdown of TRIM29 led to ectopic keratin localization of keratinocytes. In primary tumors, lower TRIM29 expression correlated with the altered expression of keratins. Our findings reveal an unexpected role for TRIM29 in regulating the distribution of keratins, as well as in the migration and invasion of SCC. They also suggest that the TRIM29-keratin axis could serve as a diagnostic and prognostic marker in stratified epithelial tumors and may provide a target for SCC therapeutics. SIGNIFICANCE: These findings identify TRIM29 as a novel diagnostic and prognostic marker in stratified epithelial tissues. - ダーモスコープを用いた術後植皮片の観察
北村 真也; 柳 輝希; 高島 有香; 今福 恵輔; 秦 洋郎; 清水 宏; 藤岡 容一朗; 大場 雄介
日本皮膚科学会雑誌, 128, 12, 2665, 2665, (公社)日本皮膚科学会, 2018年11月
日本語 - 皮膚有棘細胞癌におけるDrp1の機能解析
北村 真也; 柳 輝希; 今福 恵輔; 秦 洋郎; 清水 宏; 阿部 理一郎
日本皮膚科学会雑誌, 128, 8, 1663, 1663, (公社)日本皮膚科学会, 2018年07月
日本語 - Dermoscopic features of Bednar tumor: Report of a case.
Takuya Maeda; Yoshinobu Watabe; Teruki Yanagi; Keisuke Imafuku; Shinya Kitamura; Hiroo Hata; Toshifumi Nomura; Hiroshi Shimizu
The Journal of dermatology, 45, 7, e179-e180, 2018年07月, [国際誌]
英語 - Case of successfully switching from nivolumab to vemurafenib with oral corticosteroids.
Keisuke Imafuku; Koji Yoshino; Kei Yamaguchi; Satoshi Tsuboi; Kuniaki Ohara; Hiroo Hata
The Journal of dermatology, 45, 6, e156, 2018年06月, [国際誌]
英語 - Horn-like tumour on the dorsal hand.
Hideyuki Kosumi; Teruki Yanagi; Takuya Maeda; Tatsuro Sugai; Keisuke Imafuku; Hiroo Hata; Hiroshi Shimizu
The Lancet. Infectious diseases, 18, 6, 696, 696, 2018年06月, [国際誌]
英語, 研究論文(学術雑誌) - 落葉状天疱瘡合併の悪性黒色腫に免疫チェックポイント阻害薬を投与した1例
前田 拓哉; 柳 輝希; 今福 恵輔; 北村 真也; 秦 洋郎; 泉 健太郎; 氏家 英之; 岩田 浩明; 清水 宏
日本皮膚科学会雑誌, 128, 5, 1232, 1232, (公社)日本皮膚科学会, 2018年05月
日本語 - Successful treatment of hidradenitis suppurativa with rituximab for a patient with idiopathic carpotarsal osteolysis and chronic active antibody-mediated rejection.
Kanae Takahashi; Teruki Yanagi; Shinya Kitamura; Hiroo Hata; Keisuke Imafuku; Daiki Iwami; Kiyohiko Hotta; Ken Morita; Nobuo Shinohara; Hiroshi Shimizu
The Journal of dermatology, 45, 5, e116-e117, 2018年05月, [国際誌]
英語 - Dermoscopic evaluation for skin grafts after surgery; neo-vascularization correlates with survival of skin grafts: A prospective study.
Shinya Kitamura; Teruki Yanagi; Yuka Inamura-Takashima; Keisuke Imafuku; Hiroo Hata; Yoichiro Fujioka; Yusuke Ohba; Hiroshi Shimizu
Journal of dermatological science, 90, 2, 213, 216, 2018年05月, [国際誌]
英語 - 足底に発生した複合型母斑と悪性黒色腫のダーモスコピーによる鑑別点
前田 拓哉; 秦 洋郎; 柳 輝希; 今福 恵輔; 北村 真也; 本間 英里奈; 藤田 靖幸; 清水 宏
日本臨床皮膚科医会雑誌, 35, 2, 385, 385, 日本臨床皮膚科医会, 2018年04月
日本語 - 悪性黒色腫の骨転移に対してデノスマブが有効であった1例
秦 洋郎; 前田 拓哉; 今福 恵輔; 北村 真也; 柳 輝希; 藤村 卓; 清水 宏
日本臨床皮膚科医会雑誌, 35, 2, 388, 388, 日本臨床皮膚科医会, 2018年04月
日本語 - Apocrine mixed tumour on the abdomen: an atypical location.
Shoko Mai; Yasuyuki Fujita; Tatsurou Sugai; Keisuke Imafuku; Hiroo Hata; Satoru Shinkuma; Toshifumi Nomura; Naoki Kawagishi; Hiroshi Shimizu
European journal of dermatology : EJD, 28, 2, 234, 235, 2018年04月01日, [国際誌]
英語, 研究論文(学術雑誌) - Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study.
Taku Fujimura; Yota Sato; Kayo Tanita; Yumi Kambayashi; Atsushi Otsuka; Yasuhiro Fujisawa; Koji Yoshino; Shigeto Matsushita; Takeru Funakoshi; Hiroo Hata; Yuki Yamamoto; Hiroshi Uchi; Yumi Nonomura; Ryota Tanaka; Megumi Aoki; Keisuke Imafuku; Hisako Okuhira; Sadanori Furudate; Takanori Hidaka; Setsuya Aiba
Oncotarget, 9, 21, 15542, 15551, 2018年03月20日, [国際誌]
英語, 研究論文(学術雑誌), Antibodies against PD-1, such as nivolumab and pembrolizumab, are widely used in the treatment of various cancers including advanced melanoma. The anti-PD-1 Ab significantly prolongs survival in patients with metastatic melanoma, and its administration in combination with local or systemic therapy may also lead to improved outcomes. Although anti-PD-1 Ab-based combined therapy might be effective for the treatment of advanced melanoma, the associated risk of irAEs is an important consideration. Therefore, being able to predict irAEs is of great interest to oncologists. The purpose of this study was to evaluate the value of using serum levels of sCD163 and CXCL5 to predict irAEs in patients with advanced melanoma who were administered nivolumab. To this end, we analyzed these serum levels in 46 cases of advanced melanoma treated with nivolumab. In addition, the tumor stroma was evaluated by immunohistochemistry and immunofluorescence. We measured the serum levels of sCD163 and CXCL5 on day 0 (immediately before nivolumab administration) and day 42. The serum absolute levels of sCD163 were significantly increased in patients who developed AEs (p = 0.0018). Although there was no significant difference in serum levels of CXCL5, the absolute value of CXCL5 could at least be a supportive marker for the increased absolute levels of serum sCD163. This study suggests that sCD163 and CXCL5 may serve as possible prognostic biomarkers for irAEs in patients with advanced melanoma treated with nivolumab. - Six-month History of a Split Thumbnail: A Quiz.
Yosuke Mai; Hideyuki Ujiie; Takashi Anan; Hajime Miyazawa; Keisuke Imafuku; Kokichi Hamasaka; Hiroshi Shimizu
Acta dermato-venereologica, 98, 2, 297, 298, 2018年02月07日, [国際誌]
英語, 研究論文(学術雑誌) - 足底に発生した複合型母斑の悪性黒色腫との鑑別点
前田 拓哉; 秦 洋郎; 柳 輝希; 今福 恵輔; 北村 真也; 本間 英里奈; 藤田 靖幸; 清水 宏
日本皮膚科学会雑誌, 128, 2, 197, 203, (公社)日本皮膚科学会, 2018年02月
日本語 - 落葉状天疱瘡合併悪性黒色腫に免疫チェックポイント阻害薬を投与した1例
前田 拓哉; 柳 輝希; 今福 恵輔; 北村 真也; 秦 洋郎; 泉 健太郎; 氏家 英之; 岩田 浩明; 清水 宏
日本皮膚科学会雑誌, 128, 1, 61, 61, (公社)日本皮膚科学会, 2018年01月
日本語 - ベムラフェニブおよびデノスマブ投与にて加療したBRAF遺伝子変異陽性悪性黒色腫の1例
今福 恵輔; 秦 洋郎; 前田 拓哉; 北村 真也; 柳 輝希; 清水 宏
日本皮膚科学会雑誌, 128, 1, 63, 63, (公社)日本皮膚科学会, 2018年01月
日本語 - 爪線状苔癬の1例
眞井 洋輔; 氏家 英之; 宮澤 元; 今福 恵輔; 清水 宏; 阿南 隆; 浜坂 幸吉
日本皮膚科学会雑誌, 128, 1, 64, 64, (公社)日本皮膚科学会, 2018年01月
日本語 - Lipofuscin deposition causes the pigmentation of apocrine hidrocystoma.
Shinya Kitamura; Teruki Yanagi; Keisuke Imafuku; Hiroo Hata; Hiroshi Shimizu
The Journal of dermatology, 45, 1, 91, 94, 2018年01月, [国際誌]
英語, 研究論文(学術雑誌), Apocrine hidrocystoma (AHC) is a benign cystic lesion arising from apocrine glands and frequently presents as a blue hae with a whitish gloss. It has been reported that the amount of lipofuscin and the degree of its oxidation determines the pigmentation of AHC. However, little is known about the correlation between clinical color and lipofuscin granules. In this study, we histopathologically investigated three cases of AHC and statistically analyzed the quantitative correlation between the clinical color tone and the amount of cytoplasmic lipofuscin deposits. The color tone was quantified as the mean gray value using Image J software. Statistical analysis showed a negative correlative tendency (P = 0.09) between the color tone and the amount of lipofuscin. Our study suggests that the color tone of AHC is associated with the amount of lipofuscin. - Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients.
Yasuhiro Fujisawa; Koji Yoshino; Atsushi Otsuka; Takeru Funakoshi; Hiroshi Uchi; Taku Fujimura; Shigeto Matsushita; Hiroo Hata; Hisako Okuhira; Ryota Tanaka; Kojiro Nagai; Yoshihiro Ishida; Yoshio Nakamura; Sadanori Furudate; Kentaro Yamamura; Keisuke Imafuku; Yuki Yamamoto
Journal of dermatological science, 89, 1, 60, 66, 2018年01月, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: Due to resistance and immune-related adverse events (irAE) some melanoma patients require ipilimumab after nivolumab therapy. However, little is known about the result of this switching. OBJECTIVE: Investigate the outcome of ipilimumab switching in Japanese patients. METHODS: We retrospectively collected 60 patients who were treated with ipilimumab after nivolumab from 9 institutes in Japan. Information of the primary tumor, treatment, response, irAE), and survival was collected. RESULTS: In our cohort, acral lentiginous and mucosal melanoma accounted for 53% of the cases. The most common reason for initiating ipilimumab was disease progression (93%). Median interval from the last nivolumab administration to first ipilimumab administration was 29days. Only 38% of patients completed 4 injections of ipilimumab. The best overall response was 3.6%. IrAE occurred in 78% of patients and 70% of those were of grade 3/4 (G3/4) and 31% of patients experienced 2 or more irAEs. An within interval of 28days or less between the last nivolumab administration and ipilimumab administration was correlated with the development of G3/4 pyrexia and 3 or more irAEs, but irAE occurrence did not affect survival. Multivariate analysis showed that endocrine irAE (relative risk=0.22, P=0.015) and skin irAE (relative risk=2.78, P=0.048) were significant factors associated with survival. CONCLUSION: In our study, the response ratio to ipilimumab after nivolumab was unsatisfactory and associated with a high frequency of severe irAEs. As there are few second-line treatment options for patients with BRAF wild-type advanced melanoma after nivolumab failure, patients should be closely monitored if ipilimumab is initiated. - Enhanced IL-34 expression in Nivolumab-resistant metastatic melanoma.
Nanumi Han; Muhammad Baghdadi; Kozo Ishikawa; Hiraku Endo; Takuto Kobayashi; Haruka Wada; Keisuke Imafuku; Hiroo Hata; Ken-Ichiro Seino
Inflammation and regeneration, 38, 3, 3, 2018年, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: Immunotherapies that target immune-checkpoint molecules such PD-1 have helped to achieve durable responses in melanoma treatment. However, 25% of melanoma patients who showed objective responses to PD-1 blockade develop resistance and suffer from disease progression and ultimately death, which necessitates the identification of related resistance mechanisms.IL-34 is a cytokine that controls the biology of myeloid cell lineage through binding to CSF-1R. IL-34 is importantly involved in the pathogenesis of various diseases. In cancer, the expression of IL-34 has been suggested to associate with tumor growth, metastasis, angiogenesis, and therapeutic resistance such as in lung cancers and malignant pleural mesotheliomas. In this study, we evaluate the possible involvement of IL-34 in immunotherapeutic resistance. CASE PRESENTATION: Melanoma resection species were obtained from a patient who developed a refractory melanoma against immunotherapy with Nivolumab, and stained with anti-IL-34, anti-melanoma antigens and anti-CD163 antibody. Staining of these markers was compared between primary or metastatic refractory melanoma tissues. Immunohistochemistry staining of melanoma tissues showed an enhanced expression of IL-34 in metastatic refractory melanoma compared to primary melanoma tissues, which correlates with increased frequencies of CD163+ macrophages. CONCLUSION: We introduce for the first time a clinical case of a patient with metastatic refractory melanoma that acquired resistance to anti-PD-1 immunotherapy, showing an enhanced expression of IL-34 in refractory melanoma tissues. - Serum Level of Soluble CD163 May Be a Predictive Marker of the Effectiveness of Nivolumab in Patients With Advanced Cutaneous Melanoma.
Taku Fujimura; Yota Sato; Kayo Tanita; Yumi Kambayashi; Atsushi Otsuka; Yasuhiro Fujisawa; Koji Yoshino; Shigeto Matsushita; Takeru Funakoshi; Hiroo Hata; Yuki Yamamoto; Hiroshi Uchi; Yumi Nonomura; Ryota Tanaka; Megumi Aoki; Keisuke Imafuku; Hisako Okuhira; Naoko Wada; Hiroyuki Irie; Takanori Hidaka; Akira Hashimoto; Setsuya Aiba
Frontiers in oncology, 8, 530, 530, 2018年, [国際誌]
英語, 研究論文(学術雑誌), Antibodies against programmed cell death protein 1, such as nivolumab and pembrolizumab, are widely used for treating various cancers, including advanced melanoma. Nivolumab significantly prolongs survival in patients with metastatic melanoma, and sequential administration with lipilimumab may improve outcomes when switched at the appropriate time. Biomarkers are therefore needed to evaluate nivolumab efficacy soon after first administration. This study analyzed serum levels of soluble cluster of differentiation 163 (sCD163) in 59 cases of advanced cutaneous melanoma and 16 cases of advanced mucosal melanoma treated using nivolumab. Serum levels of sCD163 were significantly increased after 6 weeks in responders compared to non-responders after initial administration of nivolumab for cutaneous melanoma. In contrast, no significant difference between responders and non-responders was seen among patients with non-cutaneous melanoma. These results suggest that sCD163 may be useful as a biomarker for selecting patients with advanced cutaneous melanoma most likely to benefit from anti-melanoma immunotherapy. - Autoantibodies of non-inflammatory bullous pemphigoid hardly deplete type XVII collagen of keratinocytes.
Keisuke Imafuku; Hiroaki Iwata; Mayumi Kamaguchi; Kentaro Izumi; Ken Natsuga; Hideyuki Ujiie; Wataru Nishie; Hiroshi Shimizu
Experimental dermatology, 26, 12, 1171, 1174, 2017年12月, [国際誌]
英語, Type XVII collagen (COL17) and the non-collagenous 16A (NC16A) domain is regarded as the major pathogenic domains for bullous pemphigoid (BP). Some patients with BP have autoantibodies against parts of COL17 outside the NC16A domain (hereinafter the non-NC16A domain) and show less inflammatory manifestations. There were no significant differences in titres and IgG subclasses between NC16A-BP and non-NC16A-BP as determined by indirect immunofluorescent microscopy. The neutrophil activation capacities determined by ROS release did not differ between NC16A-BP and non-NC16A-BP. However, NC16A-BP IgG depleted COL17 in a dose-dependent manner. Treatment with NC16A-BP IgG, but not with non-NC16A-BP IgG, significantly decreased the adhesion strength. We speculate that the differences in clinical severity between NC16A-BP and non-NC16A-BP relate to the degree of COL17 depletion. - Comprehensive cancer-related gene analysis reveals that active KRAS mutation is a prognostic mutation in mycosis fungoides.
Teruki Yanagi; Hiroshi Nishihara; Kyoko Fujii; Machiko Nishimura; Atsushi Narahira; Kanae Takahashi; Hiroaki Iwata; Hiroo Hata; Shinya Kitamura; Keisuke Imafuku; Hiroshi Shimizu
Journal of dermatological science, 88, 3, 367, 370, 2017年12月, [国際誌]
英語 - Using immune checkpoint inhibitors without exacerbation in a melanoma patient with pemphigus foliaceus.
Takuya Maeda; Teruki Yanagi; Keisuke Imafuku; Shinya Kitamura; Hiroo Hata; Kentaro Izumi; Hideyuki Ujiie; Hiroaki Iwata; Hiroshi Shimizu
International journal of dermatology, 56, 12, 1477, 1479, 2017年12月, [国際誌]
英語 - Disappearing subcutaneous papules and nodules: Characteristic features of muscle herniation and piezogenic pedal papules.
Yosuke Mai; Wataru Nishie; Tatsuro Sugai; Keisuke Imafuku; Ken Arita; Hiroshi Shimizu
The Journal of dermatology, 44, 12, e361-e362, 2017年12月, [国際誌]
英語 - Drp1 regulates mitochondrial morphology and cell proliferation in cutaneous squamous cell carcinoma.
Shinya Kitamura; Teruki Yanagi; Keisuke Imafuku; Hiroo Hata; Riichiro Abe; Hiroshi Shimizu
Journal of dermatological science, 88, 3, 298, 307, 2017年12月, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: Dynamin-related protein 1 (Drp1) mediates mitochondrial fission. Recently, several studies have shown that Drp1 plays an important role in some cancers. However, little is known about Drp1 in cutaneous squamous cell carcinoma (SCC). OBJECTIVE: To investigate the role of Drp1 in the tumorigenesis of cutaneous SCCs. METHODS AND RESULTS: We investigated cell proliferation, cell cycle, mitochondrial morphology, and MAPK signaling pathway using cutaneous SCC A431 and DJM1 cells that were transfected with shRNA vectors targeting Drp1. The Drp1 gene-knockdown SCC cells showed lower cell proliferation than scramble-control cells, as assessed by direct cell counting and clonogenic assays. DNA content analysis showed Drp1 knockdown to cause G2/M arrest. Morphologically, the depletion of Drp1 resulted in an elongated, hyper-fused mitochondrial network. The MEK inhibitor PD325901 suppressed cell proliferation, as well as inhibiting the phosphorylation of ERK1/2 and Drp1Ser616. Also, PD325901 caused the dysregulation of the mitochondrial network. In tumor xenografts of DJM1 cells, the knockdown of Drp1 suppressed tumor growth in vivo, and clinically, the expression levels of Drp1 were higher in cutaneous SCCs than in normal epidermis, and correlated positively with the advanced clinical stages. CONCLUSION: Our results reveal a crucial function for Drp1 in regulating tumor growth, mitochondrial morphology, and cell cycle in cutaneous SCC, suggesting that Drp1 could be a novel target for skin tumor therapies. - Photodynamic eye precisely reveals pilonidal sinus borders.
Takuya Maeda; Teruki Yanagi; Keisuke Imafuku; Shinya Kitamura; Hiroo Hata; Hiroshi Shimizu
International journal of dermatology, 56, 12, 1514, 1515, 2017年12月, [国際誌]
英語 - Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumab.
Yasuhiro Fujisawa; Koji Yoshino; Atsushi Otsuka; Takeru Funakoshi; Taku Fujimura; Yuki Yamamoto; Hiroo Hata; Masahiko Gosho; Ryota Tanaka; Kei Yamaguchi; Yumi Nonomura; Ikuko Hirai; Sadanori Furudate; Hisako Okuhira; Keisuke Imafuku; Megumi Aoki; Shigeto Matsushita
Journal of dermatological science, 88, 2, 225, 231, 2017年11月, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: Although nivolumab significantly prolongs survival of metastatic melanoma, about 10% of patients experience severe, even fatal immune-related adverse events (irAEs). Biomarkers to predict irAEs are, therefore, of great interest. OBJECTIVE: We aimed to correlate changes in routine blood count parameters to the occurrence of serious irAEs (grade 3/4 [G3/4] or lung/gastrointestinal [lung/GI] irAEs) in patients with melanoma who were treated with nivolumab. METHODS: We retrospectively analyzed data from 101 patient with melanoma treated with nivolumab from 8 institutes in Japan. We used logistic regression analyses to investigate associations between severe irAEs and fluctuations in routine blood count parameters (total white blood cell [WBC] count, relative neutrophil, monocyte, lymphocyte, and eosinophil count) during the treatment. Receiver-operating characteristic curve was used to determine a cutoff value for the blood count parameters and area under the curve (AUC). RESULTS: Univariate analysis revealed that G3/4 irAEs were associated with increased total WBC count (P=0.034, cutoff value=+27%, AUC=0.68, odds ratio [OR]=1.58) and decreased relative lymphocyte count (RLC, P=0.042, cutoff value=-23%, AUC=0.65, OR=1.65). However, multivariate analysis showed that the same factors, increased WBC count (P=0.014, cutoff value=+59.1%, AUC=0.79, OR=6.04) and decreased RLC (P=0.012, cutoff value=-32.3%, AUC=0.81, OR=5.01) were independent factors associated with lung/GI irAEs. CONCLUSIONS: Our results suggest that increased WBC count and decreased RLC are associated with G3/4 and lung/GI irAEs. Our analysis was based on the data point at which irAE occurrence was noticed and, therefore, these factors are not predictive, however, they could be a "signal" of severe irAE occurrence in patients with melanoma treated with nivolumab. - Subcutaneous Nodule on the Right Palm of a Young Boy: A Quiz.
Takuya Maeda; Yasuyuki Fujita; Keisuke Imafuku; Shinichi Nakazato; Hiroo Hata; Toshifumi Nomura; Tomoko Mitsuhashi; Takashi Anan; Tadashi Hasegawa; Shuji Hamaoka; Hiroshi Shimizu
Acta dermato-venereologica, 97, 9, 1150, 1151, 2017年10月02日, [国際誌]
英語, 研究論文(学術雑誌), is missing (Quiz). - Adjuvant therapy with low-dose interferon-beta for stage II and III melanoma: results of a retrospective analysis
T. Yanagi; H. Hata; E. Homma; S. Kitamura; K. Imafuku; H. Shimizu
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 42, 7, 781, 785, 2017年10月, [査読有り]
英語, 研究論文(学術雑誌) - Ultrasonographic features of intravascular fasciitis: case report and review of the literature
K. Takahashi; T. Yanagi; K. Imafuku; S. Kitamura; Y. Inamura-Takashima; Y. Yamaguchi; H. Hata; H. Shimizu
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 31, 10, E457, E459, 2017年10月, [査読有り]
英語 - インフリキシマブが有効であった潰瘍性大腸炎合併化膿性汗腺炎の1例
真屋 由佳; 柳 輝希; 高島 有香; 今福 恵輔; 北村 真也; 伊東 孝政; 秦 洋郎; 清水 宏
皮膚科の臨床, 59, 11, 1753, 1757, 金原出版(株), 2017年10月
日本語, 37歳女。約5年前より腋窩や鼠径に毛嚢炎を繰り返し、紹介受診時には両鼠径、会陰部、左腋窩に圧痛と排膿、瘻孔を伴う多数の紅色丘疹および瘢痕性局面を認め、化膿性汗腺炎と診断して各種抗菌薬を開始するも奏効しなかった。経過中に中等度以上の潰瘍性大腸炎を合併し、プレドニゾロン、メサラジンを開始したが、腹部症状の改善は乏しく、鼠径や腋窩の皮膚症状に著変はなかった。そこで、インフリキシマブを開始したところ、腹部症状が消失し、炎症所見の陰性化とともに皮膚症状と疼痛の消失も得られ、インフリキシマブ投与2ヵ月後の下部消化管内視鏡検査では肉眼的に炎症所見の著明な改善を認めた。インフリキシマブ投与終了2ヵ月後も皮膚症状の再燃はなく、左腋窩と両鼠径部の瘢痕を外科的に切除し得た。インフリキシマブは化膿性汗腺炎の病勢コントロールに大きく寄与したと考えられた。 - Seborrheic keratosis arising on an epidermal nevus with HRAS p.G13R mutation.
Shinya Kitamura; Teruki Yanagi; Keisuke Imafuku; Hiroo Hata; Kyoko Fujii; Hiroshi Nishihara; Hiroshi Shimizu
International journal of dermatology, 56, 9, e177-e180, 2017年09月, [国際誌]
英語 - Usefulness of dermoscopy in distinguishing benign lesions from angiosarcoma
T. Sanada; H. Hata; K. Sato; K. Imafuku; S. Kitamura; T. Yanagi; T. Nomura; H. Shimizu
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 42, 6, 676, 678, 2017年08月, [査読有り]
英語 - A case of linear basal cell carcinoma: evaluation of proliferative activity by immunohistochemical staining of PCTAIRE1 and p27
Y. Yamaguchi; T. Yanagi; K. Imafuku; S. Kitamura; H. Hata; H. Nishihara; H. Shimizu
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 31, 8, E359, E362, 2017年08月, [査読有り]
英語 - ニボルマブによるpseudoprogressionに関するエコー所見の検討
今福 恵輔; 秦 洋郎; 北村 真也; 柳 輝希; 清水 宏
日本皮膚科学会雑誌, 127, 9, 2113, 2113, (公社)日本皮膚科学会, 2017年08月
日本語 - Nivolumab投与中に消化管転移を来した悪性黒色腫の2例
宮澤 元; 柳 輝希; 山口 泰之; 今福 恵輔; 北村 真也; 秦 洋郎; 清水 宏; 上原 治朗; 市川 伸樹; 大野 陽介; 吉田 雅; 本間 重紀; 川村 秀樹; 武冨 紹信
日本皮膚科学会雑誌, 127, 9, 2117, 2117, (公社)日本皮膚科学会, 2017年08月
日本語 - インフリキシマブが有効であった潰瘍性大腸炎合併化膿性汗腺炎の1例
真屋 由佳; 柳 輝希; 高島 有香; 今福 恵輔; 北村 真也; 伊東 孝政; 秦 洋郎; 清水 宏
日本皮膚科学会雑誌, 127, 9, 2120, 2120, (公社)日本皮膚科学会, 2017年08月
日本語 - 腹部に生じたapocrine mixed tumorの1例
眞井 翔子; 藤田 靖幸; 須貝 達朗; 今福 恵輔; 秦 洋郎; 新熊 悟; 乃村 俊史; 清水 宏
日本皮膚科学会雑誌, 127, 9, 2120, 2120, (公社)日本皮膚科学会, 2017年08月
日本語 - 両下腿に生じたmuscle herniationの1例
眞井 洋輔; 西江 渉; 須貝 達朗; 今福 恵輔; 清水 宏; 有田 賢
日本皮膚科学会雑誌, 127, 9, 2120, 2120, (公社)日本皮膚科学会, 2017年08月
日本語 - Myxoinflammatory fibroblastic sarcomaの1例
前田 拓哉; 藤田 靖幸; 秦 洋郎; 今福 恵輔; 中里 信一; 清水 宏; 三橋 智子; 長谷川 匡; 阿南 隆; 浜岡 秀爾
日本皮膚科学会雑誌, 127, 9, 2122, 2122, (公社)日本皮膚科学会, 2017年08月
日本語 - Two cases of melanomas paradoxically metastasizing to the intestinal tract during nivolumab therapy.
Hajime Miyazawa; Teruki Yanagi; Yasuyuki Yamaguchi; Keisuke Imafuku; Shinya Kitamura; Hiroo Hata; Jiro Uehara; Nobuki Ichikawa; Yosuke Ohno; Tadashi Yoshida; Shigenori Homma; Hideki Kawamura; Akinobu Taketomi; Hiroshi Shimizu
The Journal of dermatology, 44, 8, 959, 962, 2017年08月, [国際誌]
英語, 研究論文(学術雑誌), We report two cases of melanomas in patients who developed intestinal metastasis despite other metastatic sites responding to nivolumab and despite the patients having favorable findings such as vitiligo and normal lactate dehydrogenase. The first case is an 85-year-old man who had been administrated nivolumab for lung/cutaneous metastases. After 22 courses of nivolumab therapy, fever and anorexia had appeared and his bodyweight had decreased. An intussusception on the ileocecal valve was revealed by computed tomography, and emergency surgery revealed metastatic lesions on the colon. The second case is an 87-year-old woman treated with nivolumab for lymph node metastases. After 10 courses, laboratory tests had revealed anemia and positive fecal occult blood. Her bodyweight had decreased. Capsule endoscopy showed scattered tumors and clots, indicating metastases of melanoma. The frequency of symptomatic intestinal metastasis of melanoma is very low. Further, intestinal metastasis of melanoma is difficult to detect through routine examinations. Our cases suggest that fecal occult blood test and decreased bodyweight are indications of intestinal metastases. - Multiple skin cancers in patients with mycosis fungoides after long-term ultraviolet phototherapy
K. Imafuku; H. Hata; T. Yanagi; S. Kitamura; Y. Inamura-Takashima; M. Nishimura; S. Kitamura; S. Moriwaki; H. Shimizu
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 42, 5, 523, 526, 2017年07月, [査読有り]
英語, 研究論文(学術雑誌) - Nivolumab使用後にipilimumabを投与した際の副作用出現についての考察
今福 恵輔; 吉野 公二; 山口 慶; 壷井 聡史; 大原 國章; 秦 洋郎
日本皮膚悪性腫瘍学会学術大会プログラム・抄録集, 33回, 163, 163, (一社)日本皮膚悪性腫瘍学会, 2017年05月
日本語 - Nivolumab投与中に消化管転移を来した悪性黒色腫の2例
宮澤 元; 柳 輝希; 山口 泰之; 今福 恵輔; 北村 真也; 秦 洋郎; 上原 治朗; 本間 重紀; 武冨 紹信; 清水 宏
日本皮膚科学会雑誌, 127, 5, 1140, 1140, (公社)日本皮膚科学会, 2017年05月
日本語 - Two cases of successful treatment for severe skin rash induced by vemurafenib following nivolumab therapy without cessation of vemurafenib.
Satoshi Tsuboi; Koji Yoshino; Kei Yamaguchi; Keisuke Imafuku; Kuniaki Ohara
The Journal of dermatology, 44, 5, 607, 608, 2017年05月, [国際誌]
英語 - PCTAIRE1/CDK16/PCTK1 is overexpressed in cutaneous squamous cell carcinoma and regulates p27 stability and cell cycle.
Teruki Yanagi; Hiroo Hata; Eri Mizuno; Shinya Kitamura; Keisuke Imafuku; Shinichi Nakazato; Lei Wang; Hiroshi Nishihara; Shinya Tanaka; Hiroshi Shimizu
Journal of dermatological science, 86, 2, 149, 157, 2017年05月, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: PCTAIRE1 (also known as cyclin-dependent kinase 16 (Cdk16) and PCTK1) is a Cdk family protein that has been implicated in spermatogenesis. We recently revealed the function of PCTAIRE1 in the tumorigenesis of malignancies, including breast and prostate cancers; however, the tumorigenic function of PCTAIRE1 in cutaneous squamous cell carcinoma (SCC) remains unclear. OBJECTIVE: In this study, we investigated the role of PCTAIRE1 in the tumorigenesis of cutaneous SCCs. METHODS AND RESULTS: In cutaneous/oral SCC A431, DJM-1, HSC-3 cells, PCTAIRE1 gene-knockdown was found to diminish cell proliferation as assessed by cell counting and clonogenic assays. FACS analyses of annexin V-PI staining and DNA content showed PCTAIRE1 knockdown to cause G2/M arrest followed by apoptosis. The depletion of PCTAIRE1 was found to lead to the accumulation of tumor suppressor p27 and down-regulation of c-Myc. In tumor xenografts of A431 cells, the conditional knockdown of PCTAIRE1 restores p27 protein expression and suppresses tumor growth. Clinically, in primary tumors from patients with SCC, PCTAIRE1 is more highly expressed in malignant lesions than in adjacent normal epidermis. Conversely, expression levels of p27 are significantly lower in SCC than in normal epidermis. CONCLUSIONS: Our findings reveal a crucial function for PCTAIRE1 in regulating p27, c-Myc levels and tumor growth in cutaneous SCC cells, suggesting that PCTAIRE1 could be a novel target for skin tumor treatment. - Successful Treatment of Sudden Hepatitis Induced by Long-Term Nivolumab Administration
Keisuke Imafuku; Koji Yoshino; Kei Yamaguchi; Satoshi Tsuboi; Kuniaki Ohara; Hiroo Hata
Case Reports in Oncology, 10, 1, 368, 371, S. Karger {AG}, 2017年04月24日, [国際誌]
英語, 研究論文(学術雑誌), Immune checkpoint inhibitors have drastically changed in the treatment of many kinds of malignancies, especially malignant melanoma. The focus of the recent experiments has not only been on their efficacy but also immune-related adverse events (irAEs). We report a case of fulminant hepatitis due to nivolumab. In this case, the patient had undergone long-term nivolumab therapy. He did not complain of any symptoms but his liver enzyme levels were extremely elevated (grade 4). We promptly decided to start oral corticosteroids in the patient. His liver function rapidly improved. The dose of corticosteroids was gradually reduced. Our case demonstrates that sudden onset fulminant hepatitis can occur despite the safe use of long-term nivolumab therapy. The irAE can improve rapidly with proper corticosteroid treatment. This report will be useful for the physicians who always use immune checkpoint inhibitors. - Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy'.
Keisuke Imafuku; Koji Yoshino; Kei Yamaguchi; Satoshi Tsuboi; Kuniaki Ohara; Hiroo Hata
British journal of cancer, 116, 8, e14, 2017年04月11日, [国際誌]
英語 - Two Cases of Nivolumab Re-Administration after Pneumonitis as Immune-Related Adverse Events
Keisuke Imafuku; Koji Yoshino; Kei Yamaguchi; Satoshi Tsuboi; Kuniaki Ohara; Hiroo Hata
Case Reports in Oncology, 10, 1, 296, 300, S. Karger {AG}, 2017年04月04日, [国際誌]
英語, 研究論文(学術雑誌), Nivolumab is a recently approved medication for the treatment of unresectable malignant melanoma. Many immune-related adverse events (irAEs) associated with nivolumab have been reported, such as pneumonitis, hepatitis, dermatitis, and thyroiditis. Prednisolone can effectively treat irAEs. However, it is unclear how or if nivolumab should be administered to patients after they have experienced an irAE. Herein, we show 2 patients who underwent pneumonitis as irAE. Case 1 demonstrated a cryptogenic organizing pneumonia pattern in the CT scan and case 2 had a diffuse alveolar damage (DAD) pattern. Oral corticosteroids improved chest shadow of CT scan in both cases. However, when nivolumab was re-administrated, case 1 demonstrated no symptoms, but case 2 demonstrated pneumonia again. From our cases, it is difficult to re-administrate nivolumab for the patients with pneumonitis which shows a DAD pattern in CT, even if oral corticosteroids improve their symptoms. - Sudden Onset of Brain Metastasis despite the Use of Vemurafenib for Another Metastatic Lesion in Malignant Melanoma Patients
Keisuke Imafuku; Koji Yoshino; Kei Yamaguchi; Satoshi Tsuboi; Kuniaki Ohara; Hiroo Hata
Case Reports in Oncology, 10, 1, 290, 295, 2017年04月04日, [国際誌]
英語, 研究論文(学術雑誌), Vemurafenib is an inhibitor of the BRAF mutation and has been approved by the Food and Drug Administration as a treatment option for patients with unresectable melanoma without brain metastasis. In the literature, vemurafenib has been reported to be also effective against brain metastasis. We encountered 3 cases with brain metastasis on vemurafenib therapy. In these cases, vemurafenib was clinically effective against metastatic lesions other than those in the brain. The brain lesions developed after the metastatic lesion had occurred. Therefore, we assume that the melanomas of the patients acquired resistance against vemurafenib. The brain metastases were treated with the cyberknife. Patients 1 and 2 without LDH elevation are still alive, but patient 3 with abnormal LDH elevation died despite the treatment. We need to carefully follow patients on vemurafenib therapy because brain metastasis can suddenly occur even if the metastatic lesion has decreased clinically. The therapeutic effect of vemurafenib against brain metastasis is poor in cases with LDH elevation. - Isolated adrenocorticotropic hormone deficiency associated with nivolumab therapy.
Atsushi Narahira; Teruki Yanagi; Kyu Yong Cho; Akinobu Nakamura; Hideaki Miyoshi; Hiroo Hata; Keisuke Imafuku; Shinya Kitamura; Hiroshi Shimizu
The Journal of dermatology, 44, 4, e70, 2017年04月, [国際誌]
英語 - Case of primary pleural angiosarcoma with malignant seeding along the pleural tap tract.
Kei Yamaguchi; Koji Yoshino; Keisuke Imafuku; Satoshi Tsuboi; Kuniaki Ohara
The Journal of dermatology, 44, 4, e75-e76, 2017年04月, [国際誌]
英語 - Case of congenital panfollicular nevus with remarkable adipose tissue proliferation.
Keiko Shiba; Teruki Yanagi; Shinichi Nakazato; Keisuke Imafuku; Shinya Kitamura; Hiroo Hata; Hiroshi Shimizu
The Journal of dermatology, 44, 4, e77-e78, 2017年04月, [国際誌]
英語 - Acrokeratoelastoidosis successfully treated with 10% salicylic acid ointment.
Chihiro Shiiya; Hiroo Hata; Yuka Inamura; Keisuke Imafuku; Shinya Kitamura; Teruki Yanagi; Yasuyuki Fujita; Hiroshi Shimizu
The Journal of dermatology, 44, 3, e46-e47, 2017年03月, [国際誌]
英語 - Hypothyroidism associated with nivolumab treatment of unresectable malignant melanoma.
Imafuku K; Yoshino K; Yamaguchi K; Tsuboi S; Ohara K; Hata H
Clinical and experimental dermatology, 2017年01月
研究論文(学術雑誌) - Zwei Fälle einer wiederholten Anwendung von Nivolumab nach einer Pneumonitis als immunvermittelte Nebenwirkung
Keisuke Imafuku; Koji Yoshino; Kei Yamaguchi; Satoshi Tsuboi; Kuniaki Ohara; Hiroo Hata
Kompass Pneumologie, 5, 3, 185, 188, S. Karger {AG}, 2017年
研究論文(学術雑誌) - Ultrasonographic findings can identify ‘pseudoprogression’ under nivolumab therapy
K. Imafuku; H. Hata; S. Kitamura; T. Yanagi; H. Shimizu
British Journal of Dermatology, 177, 6, 1726, 1731, Blackwell Publishing Ltd, 2017年, [査読有り]
英語, 研究論文(学術雑誌) - Pazopanib does not bring remarkable improvement in patients with angiosarcoma.
Shinya Kitamura; Teruki Yanagi; Yuka Inamura; Hiroo Hata; Keisuke Imafuku; Koji Yoshino; Hiroshi Shimizu
The Journal of dermatology, 44, 1, 64, 67, 2017年01月, [国際誌]
英語, 研究論文(学術雑誌), Pazopanib is a potent and selective multi-targeted tyrosine kinase inhibitor that has been reported to extend progression-free survival in cases of metastatic soft-tissue sarcoma. However, the efficacy of pazopanib for cutaneous angiosarcoma has not been confirmed. We report eight cases of angiosarcoma treated with pazopanib, and review the efficacy and safety of pazopanib therapy. We retrospectively investigated the clinical information, including age, sex, body surface area, location, performance status, lung or pleural metastasis, preceding treatment, oral dose of pazopanib, response rate, progression-free survival and adverse effects. Five of the eight patients needed to stop the pazopanib treatment due to severe adverse effects, including thrombocytopenia, anemia, drug-associated pancreatitis, acute fulminant hepatitis and general fatigue. Progression-free survival ranged 0.5-3.5 months (mean ± standard deviation, 1.81 ± 1.03). Overall survival ranged 3-26 months (14.13 ± 9.47). Six of the eight cases showed progressive disease, and two of the eight cases showed stable disease. To assess overall survival in angiosarcoma treated with pazopanib, we compared the pazopanib-treated group (n = 8) with the non-pazopanib-treated control group (n = 10). There was no significant difference between two groups (P = 0.19, log-rank test). In conclusion, our case series suggests that pazopanib does not bring remarkable improvement in patients with angiosarcoma. - Modified Dufourmentel flap, easy to design and tailor to the defect.
Keisuke Imafuku; Hiroo Hata; Yasuyuki Yamaguchi; Yuka Inamura; Shinya Kitamura; Teruki Yanagi; Hiroshi Shimizu
The Journal of dermatology, 44, 1, 68, 70, 2017年01月, [国際誌]
英語, 研究論文(学術雑誌), How to close skin defects is one of the most important considerations for skin surgeons. Rhomboid flaps are used for many types of skin defect. Such flaps, represented by the Limberg and Dufourmentel flaps, are widely used at any region of the body because they are composed of straight lines and are easy to draw. However, these valuable techniques have the disadvantage of being prone to dog-ears at a particular area of the flap. Therefore, our talented predecessors have modified these flaps in order to resolve the problems. The modified flaps they designed were difficult to draw because the modified designs were curvy and along esthetic lines. It is difficult for trainees to draw these flaps. To address this issue, we have developed newly modified rhomboid flaps that are based on the Dufourmentel flap. This flap is different from the Dufourmentel flap in omitting the top half of the diamond above the circle. Thus, the tension on the skin decreases and dog-ears are less likely to occur. In addition, our flaps are geometric and easily drawn even by novices. We believe our flap will be a promising option for closing skin defects at any site. - The Unique Dermoscopic Structure ‘Large black web’ in basal cell carcinoma on the areola
Kitamura S; Hata H; Yamaguchi Y; Imafuku K; Yanagi T; Shimizu H
Journal of the European Academy of Dermatology and Venereology, 30, 12, E221, E223, 2016年12月, [査読有り]
英語 - Lessons from 20 cases of digit malignant melanoma
S. Kitamura; H. Hata; Y. Inamura; K. Imafuku; K. Muramatsu; T. Yanagi; H. Shimizu
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 30, 11, E161, E163, 2016年11月, [査読有り]
英語 - A case of Stewart-Treves syndrome with the longest lag: 44 years after radical mastectomy for breast cancer.
Yuka Inamura; Hiroo Hata; Keisuke Imafuku; Shinya Kitamura; Hiroshi Shimizu
The Australasian journal of dermatology, 57, 4, e146-e147, 2016年11月, [国際誌]
英語 - Dermoscopic findings of irritated seborrheic keratosis
S. Kitamura; H. Hata; K. Imafuku; Y. Fujita; H. Shimizu
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 30, 10, E94, E96, 2016年10月, [査読有り]
英語 - Nivolumab therapy before vemurafenib administration induces a severe skin rash.
Imafuku K; Yoshino K; Ymaguchi K; Tsuboi S; Ohara K; Hata H
Journal of the European Academy of Dermatology and Venereology : JEADV, 2016年08月
研究論文(学術雑誌) - mTOR expression correlates with invasiveness and progression of extramammary Paget's disease
H. Hata; S. Kitamura; Y. Inamura; K. Imafuku; E. Homma; K. Muramatsu; K. Natsuga; R. Abe; H. Shimizu
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 30, 7, 1238, 1239, 2016年07月, [査読有り]
英語 - Morphoeic basal cell carcinoma with ring-form ulceration.
Yuka Inamura; Keisuke Imafuku; Shinya Kitamura; Hiroo Hata; Hiroshi Shimizu
International journal of dermatology, 55, 7, e415-6, 2016年07月, [国際誌]
英語 - Vemurafenibにより腎機能障害をきたした悪性黒色腫の2例
山口 慶; 今福 恵輔; 壷井 聡史; 大原 國章; 吉野 公二
日本皮膚科学会雑誌, 126, 7, 1326, 1326, (公社)日本皮膚科学会, 2016年06月
日本語 - 色素線条がなく、爪周囲に黒色斑を認めた悪性黒色腫の2例
今福 恵輔; 山口 慶; 壷井 聡史; 大原 國章; 吉野 公二
日本皮膚科学会雑誌, 126, 7, 1326, 1326, (公社)日本皮膚科学会, 2016年06月
日本語 - 臀部粉瘤から生じた有棘細胞癌の1例
壷井 聡史; 今福 恵輔; 山口 慶; 石綿 夏織子; 大原 國章; 吉野 公二
日本皮膚科学会雑誌, 126, 7, 1328, 1328, (公社)日本皮膚科学会, 2016年06月
日本語 - Nivolumab投与後にvemurafenibを使用しhypersensitivityを生じた悪性黒色腫の1例
壷井 聡史; 今福 恵輔; 乙部 さやか; 石綿 夏織子; 大原 國章; 吉野 公二
西日本皮膚科, 78, 3, 320, 320, 日本皮膚科学会-西部支部, 2016年06月
日本語 - 汗腺癌に対するセンチネルリンパ節生検と予防的リンパ節郭清の適応の検討
今福 恵輔; 石綿 夏織子; 乙部 さやか; 壷井 聡史; 大原 國章; 吉野 公二
西日本皮膚科, 78, 3, 323, 324, 日本皮膚科学会-西部支部, 2016年06月
日本語 - 遠隔転移に対し化学療法、放射線照射を行っている外陰部乳房外パジェット病の1例
石綿 夏織子; 壷井 聡史; 今福 恵輔; 乙部 さやか; 大原 國章; 吉野 公二; 船田 信顕
西日本皮膚科, 78, 3, 324, 324, 日本皮膚科学会-西部支部, 2016年06月
日本語 - Verrucous hyperplasia associated with neuropathy from schistorrhachis
K. Imafuku; H. Hata; Y. Inamura; S. Kitamura; K. Natsuga; H. Iwata; H. Shimizu
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 30, 5, 876, 878, 2016年05月, [査読有り]
英語 - 【免疫チェックポイント阻害薬のirAE】(Part2.)どのようなirAEに対してどう対応したか(case 02) インフリキシマブを使用した間質性肺炎
今福 恵輔; 吉野 公二
Visual Dermatology, 15, 6, 576, 578, (株)学研メディカル秀潤社, 2016年05月
日本語 - 免疫チェックポイント阻害薬による副作用出現後に再投与した6例の有害事象の検討
山口 慶; 壷井 聡史; 今福 恵輔; 大原 國章; 吉野 公二
日本皮膚科学会雑誌, 126, 5, 977, 977, (公社)日本皮膚科学会, 2016年05月
日本語 - ニボルマブによる有害事象の発現と末梢血リンパ球減少率の相関についての検討
吉野 公二; 今福 恵輔; 壷井 聡史; 山口 慶; 大原 國章; 藤澤 康弘
日本皮膚科学会雑誌, 126, 5, 977, 977, (公社)日本皮膚科学会, 2016年05月
日本語 - Vemurafenib投与を行った7例における副作用の出現時期・様式の検討
壷井 聡史; 今福 恵輔; 山口 慶; 大原 國章; 吉野 公二
日本皮膚科学会雑誌, 126, 5, 978, 978, (公社)日本皮膚科学会, 2016年05月
日本語 - インターフェロンベータによる術後補助療法は病期2/3の皮膚原発悪性黒色腫の予後を改善する
柳 輝希; 秦 洋郎; 本間 英里奈; 北村 真也; 今福 恵輔; 清水 宏
日本皮膚科学会雑誌, 126, 5, 978, 978, (公社)日本皮膚科学会, 2016年05月
日本語 - 肛囲パジェット病と肛門管癌(pagetoid spread)の鑑別におけるCDX2染色の有効性について
今福 恵輔; 山口 慶; 壷井 聡史; 大原 國章; 比島 恒和; 吉野 公二
日本皮膚科学会雑誌, 126, 5, 986, 986, (公社)日本皮膚科学会, 2016年05月
日本語 - Pazopanibで加療した血管肉腫8例の検討
北村 真也; 柳 輝希; 稲村 有香; 秦 洋郎; 今福 恵輔; 吉野 公二; 清水 宏
日本皮膚科学会雑誌, 126, 6, 1126, 1126, (公社)日本皮膚科学会, 2016年05月
日本語 - ニボルマブにより甲状腺機能低下症をきたした3症例
山口 慶; 今福 恵輔; 壼井 聡史; 大原 國章; 吉野 公二
日本皮膚悪性腫瘍学会学術大会プログラム・抄録集, 32回, 117, 117, (一社)日本皮膚悪性腫瘍学会, 2016年05月
日本語 - Nivolumab投与後にvemurafenibを使用し重篤な副作用を生じた3例について
壺井 聡史; 今福 恵輔; 山口 慶; 大原 國章; 吉野 公二
日本皮膚悪性腫瘍学会学術大会プログラム・抄録集, 32回, 121, 121, (一社)日本皮膚悪性腫瘍学会, 2016年05月
日本語 - vemurafenibの有害事象とリンパ球減少に関する考察
今福 恵輔; 山口 慶; 壺井 聡史; 大原 國章; 吉野 公二
日本皮膚悪性腫瘍学会学術大会プログラム・抄録集, 32回, 152, 152, (一社)日本皮膚悪性腫瘍学会, 2016年05月
日本語 - ニボルマブによる間質性肺炎を呈した2例
今福 恵輔; 山口 慶; 壺井 聡史; 大原 國章; 吉野 公二
日本皮膚悪性腫瘍学会学術大会プログラム・抄録集, 32回, 155, 155, (一社)日本皮膚悪性腫瘍学会, 2016年05月
日本語 - 胸腔穿刺経路より胸壁浸潤をきたした胸膜原発血管肉腫の一例
山口 慶; 壺井 聡史; 今福 恵輔; 大原 國章; 吉野 公二
日本皮膚悪性腫瘍学会学術大会プログラム・抄録集, 32回, 173, 173, (一社)日本皮膚悪性腫瘍学会, 2016年05月
日本語 - Pazopanib投与により間質性肺炎を合併した頭部血管肉腫の1例
壺井 聡史; 今福 恵輔; 山口 慶; 大原 國章; 吉野 公二
日本皮膚悪性腫瘍学会学術大会プログラム・抄録集, 32回, 173, 173, (一社)日本皮膚悪性腫瘍学会, 2016年05月
日本語 - Mucosal hyperpigmentation from prophylactic minocycline for EGFR inhibitor
K. Imafuku; K. Natsuga; S. Aoyagi; H. Shimizu
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 30, 4, 690, 692, 2016年04月, [査読有り]
英語 - 【鑑別に苦慮した皮膚病(1)】<臨床例>悪性黒色腫との鑑別を要した爪部Bowen病
石綿 夏織子; 今福 恵輔; 壷井 聡史; 乙部 さやか; 大原 國章; 吉野 公二; 堀口 慎一郎
皮膚病診療, 38, 4, 395, 398, (株)協和企画, 2016年04月
日本語 - Plasma cell panniculitis, a type of morphea profunda, surrounded by congenital nevus spilus.
Chihiro Shiiya; Hiroaki Iwata; Keisuke Imafuku; Naoko Yamane; Eri Ito; Hiroshi Shimizu
European journal of dermatology : EJD, 26, 2, 210, 1, 2016年04月01日, [国際誌]
英語, 研究論文(学術雑誌) - Metal implant-induced skin ulcer mimicking scrofuloderma
S. Kitamura; K. Natsuga; K. Imafuku; E. Homma; N. Yamane; S. Aoyagi; T. Matsumura; H. Shimizu
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 30, 3, 449, 450, 2016年03月, [査読有り]
英語 - Basal Cell Carcinoma or Trichoblastoma Dermoscopic Examination of Black Macules Developing in the Same Nevus Sebaceus
Shinya Kitamura; Hiroo Hata; Keisuke Imafuku; Hiroshi Shimizu
Case Reports in Oncology, 9, 1, 143, 147, S. Karger {AG}, 2016年02月20日, [国際誌]
英語, 研究論文(学術雑誌), Nevus sebaceus (NS) is a common congenital birthmark, and various tumors have been reported to develop in NS. Basal cell carcinoma (BCC) seldom occurs in NS, and it is very important to be able to clinicopathologically distinguish BCC from trichoblastoma. Herein, we describe a case of BCC and trichoblastoma occurring simultaneously in the same NS, including the differential dermoscopic features. BCC is clinically difficult to distinguish from trichoblastoma because the clinical manifestations are similar. In a dermoscopic examination of BCC, arborizing vessels are one of the diagnostically significant features. In our case, the BCC showed 'multiple' black structures, and the trichoblastoma showed a 'single' black structure without arborizing vessels. To the best of our knowledge, there have been no reports on the dermoscopic findings of secondary tumors on NS. - A single-institution study examining cutaneous and non-cutaneous melanomas treated with nivolumab.
Imafuku K; Yoshino K; Ishiwata K; Otobe S; Tsuboi S; Ohara K; Hata H
Journal of the European Academy of Dermatology and Venereology : JEADV, 2016年02月
研究論文(学術雑誌) - 指趾に生じた末端黒子型黒色腫20例の検討
北村 真也; 秦 洋郎; 稲村 有香; 今福 恵輔; 村松 憲; 柳 輝希; 清水 宏
日本皮膚科学会雑誌, 126, 2, 165, 166, (公社)日本皮膚科学会, 2016年02月
日本語 - Vemurafenibにより薬剤性ぶどう膜炎をきたした悪性黒色腫の1例
山口 慶; 石綿 夏織子; 今福 恵輔; 壺井 聡; 大原 國章; 吉野 公二
日本皮膚科学会雑誌, 126, 2, 173, 173, (公社)日本皮膚科学会, 2016年02月
日本語 - A reddish nodule with viscous fluid secretion. Solid–cystic hidradenoma (SCH).
Keisuke Imafuku; Hiroo Hata; Chihiro Shiiya; Shinya Kitamura; Hiroshi Shimizu
International journal of dermatology, 55, 2, 151, 2, 2016年02月, [国際誌]
英語, 研究論文(学術雑誌) - Chronic papillomatous dermatitis around an ileostoma.
Shinya Kitamura; Hiroo Hata; Yuka Inamura; Keisuke Imafuku; Teruki Yanagi; Yuichiro Oishi; Satoru Maruyama; Hiroshi Shimizu
The Journal of dermatology, 43, 2, 220, 1, 2016年02月, [国際誌]
英語 - Lymphopenia can be a useful biomarker of adverse events related to vemurafenib.
Imafuku K; Yoshino K; Ishiwata K; Ymaguchi K; Tsuboi S; Ohara K; Hata H
Journal of the European Academy of Dermatology and Venereology : JEADV, 2016年01月
研究論文(学術雑誌) - 当院における粘膜悪性黒色腫9例に対するニボルマブの使用経験
今福 恵輔; 山口 慶; 石綿 夏織子; 壷井 聡史; 大原 國章; 吉野 公二
日本皮膚科学会雑誌, 126, 1, 40, 40, (公社)日本皮膚科学会, 2016年01月
日本語 - 頭部血管肉腫に対するChemoradiation therapy(CRT)後の再発・転移にPazopanibを使用した3例
壷井 聡史; 今福 恵輔; 乙部 さやか; 石綿 夏織子; 大原 國章; 吉野 公二
日本皮膚科学会雑誌, 126, 1, 45, 45, (公社)日本皮膚科学会, 2016年01月
日本語 - Weekly-Paclitaxelによる化学療法中に間質性肺炎をきたした頭部血管肉腫の1例
石綿 夏織子; 壷井 聡史; 今福 恵輔; 乙部 さやか; 山口 慶; 大原 國章; 吉野 公二; 船田 信顕
日本皮膚科学会雑誌, 126, 1, 45, 46, (公社)日本皮膚科学会, 2016年01月
日本語 - Hemosiderotic histiocytoma associated with chronic traumatic stress in a patient with spinal cord injury.
Shinya Kitamura; Hiroo Hata; Keisuke Imafuku; Hiroshi Shimizu
The Journal of dermatology, 43, 1, 109, 10, 2016年01月, [国際誌]
英語 - Positron emission tomography-computed tomography can be useful in the early detection of metastases in primary mucinous carcinoma of the skin on the head and neck
S. Kitamura; H. Hata; Y. Inamura; K. Imafuku; T. Sakashita; K. Hirata; H. Shimizu
British Journal of Dermatology, 173, 5, 1263, 1265, Blackwell Publishing Ltd, 2015年11月01日, [査読有り]
英語, 研究論文(学術雑誌) - Concomitant neoplasms in the skin and stomach unveil the role of type IV collagen and E-cadherin in mucin core protein 5AC expression in vivo.
Hata H; Natsuga K; Kitamura S; Imafuku K; Yamaguchi Y; Ebihara Y; Shichinohe T; Hirano S; Shimizu H
The British journal of dermatology, 174, 2, 395, 397, 2015年11月, [査読有り]
研究論文(学術雑誌), Hata H, Natsuga K, Kitamura S, Imafuku K, Yamaguchi Y, Ebihara Y, Shichinohe T, Hirano S, Shimizu H, The British journal of dermatology, 2016, vol. 174, no. 2, pp. 395-397 - ストマ周囲に生じた角化性結節の治療経験
北村 真也; 秦 洋郎; 稲村 有香; 今福 恵輔; 清水 宏; 大石 悠一郎; 丸山 覚
日本皮膚科学会雑誌, 125, 12, 2301, 2301, (公社)日本皮膚科学会, 2015年11月
日本語 - Stewart-Treves症候群の1例
稲村 有香; 秦 洋郎; 今福 恵輔; 北村 真也; 清水 宏
日本皮膚科学会雑誌, 125, 12, 2302, 2302, (公社)日本皮膚科学会, 2015年11月
日本語 - ニボルマブによる薬剤性肝障害を生じた悪性黒色腫の1例
石綿 夏織子; 壷井 聡史; 今福 恵輔; 山口 慶; 大原 國章; 吉野 公二
日本皮膚科学会雑誌, 125, 12, 2307, 2307, (公社)日本皮膚科学会, 2015年11月
日本語 - ニボルマブによる薬剤性腸炎を生じた悪性黒色腫の1例
今福 恵輔; 山口 慶; 石綿 夏織子; 壷井 聡史; 大原 國章; 吉野 公二
日本皮膚科学会雑誌, 125, 12, 2307, 2307, (公社)日本皮膚科学会, 2015年11月
日本語 - In-transit metastasis of advanced eccrine porocarcinoma.
Keisuke Imafuku; Hiroo Hata; Shinya Kitamura; Hiroaki Iwata; Hiroshi Shimizu
International journal of dermatology, 54, 11, e503-5, 2015年11月, [国際誌]
英語 - Dermoscopic features of hidroacanthoma simplex: Usefulness in distinguishing it from Bowen's disease and seborrheic keratosis.
Chihiro Shiiya; Hiroo Hata; Yuka Inamura; Keisuke Imafuku; Shinya Kitamura; Hiromi Fujita; Hiroshi Shimizu
The Journal of dermatology, 42, 10, 1002, 5, 2015年10月, [国際誌]
英語, 研究論文(学術雑誌), Hidroacanthoma simplex (HAS) is a rare benign eccrine adnexal tumor. HAS is sometimes clinically or pathologically misdiagnosed as squamous cell carcinoma in situ (Bowen's disease; BD), seborrheic keratosis (SK) or other adnexal tumor. To date, there has never been a report focusing on dermoscopic features to distinguish HAS from BD and SK. We found the following dermoscopic findings to be characteristic of HAS: fine black dots/globules (75% of cases) and fine scales arranged annularly (100% of cases). In contrast, glomerular vessels, which are typically observed in BD, were not seen in any of the four cases. Cerebriform appearance and milia-like cysts, which are typically observed in SK, were also not seen in any of the four cases. The existence of "scattered fine black dots/globules" and "fine scales arranged annularly", and the absence of the glomerular vessels, may contribute to precise diagnosis of HAS. Even though HAS resembles BD or SK clinically, it can be distinguished from these by the characteristic dermoscopic features. - Severe rash associated with vemurafenib administration following nivolumab therapy.
Imafuku K; Yoshino K; Ishiwata K; Otobe S; Tsuboi S; Ohara K; Hata H
Journal of the European Academy of Dermatology and Venereology : JEADV, 2015年09月
研究論文(学術雑誌) - 非典型な転移様式をたどった頬部悪性黒色腫の1例
今福 恵輔; 石綿 夏織子; 乙部 さやか; 壷井 聡史; 大原 國章; 吉野 公二
日本皮膚科学会雑誌, 125, 10, 1926, 1926, (公社)日本皮膚科学会, 2015年09月
日本語 - Pazopanibは終末期の頭部血管肉腫において整容的にQOLを維持しうる
北村 真也; 秦 洋郎; 今福 恵輔; 羽賀 直哉; 濱出 洋平; 本間 英里奈; 清水 宏
日本皮膚悪性腫瘍学会学術大会プログラム・抄録集, 31回, 131, 131, (一社)日本皮膚悪性腫瘍学会, 2015年07月
日本語 - 髄膜癌腫症を呈した外陰部パジェット病の1例
壺井 聡史; 今福 恵輔; 石綿 夏織子; 乙部 さやか; 大原 國章; 吉野 公二
日本皮膚悪性腫瘍学会学術大会プログラム・抄録集, 31回, 154, 154, (一社)日本皮膚悪性腫瘍学会, 2015年07月
日本語 - 皮膚・遠隔転移に対し化学療法、放射線照射を行った下腿eccrine porocarcinomaの一例
石綿 夏織子; 今福 恵輔; 壺井 聡史; 乙部 さやか; 大原 國章; 吉野 公二; 船田 信顕
日本皮膚悪性腫瘍学会学術大会プログラム・抄録集, 31回, 163, 163, (一社)日本皮膚悪性腫瘍学会, 2015年07月
日本語 - In-transit metastasisをきたしたprimary mucinous carcinoma of the skinの1例
本間 英里奈; 秦 洋郎; 稲村 有香; 今福 恵輔; 北村 真也; 青柳 哲; 清水 宏
日本皮膚悪性腫瘍学会学術大会プログラム・抄録集, 31回, 167, 167, (一社)日本皮膚悪性腫瘍学会, 2015年07月
日本語 - 肝転移巣が発見の契機となった脈絡膜悪性黒色腫の1例
今福 恵輔; 壺井 聡史; 石綿 夏織子; 乙部 さやか; 大原 國章; 吉野 公二
日本皮膚悪性腫瘍学会学術大会プログラム・抄録集, 31回, 176, 176, (一社)日本皮膚悪性腫瘍学会, 2015年07月
日本語 - 環状の潰瘍を呈したモルフェア型基底細胞癌の1例
稲村 有香; 秦 洋郎; 今福 恵輔; 北村 真也; 清水 宏
日本皮膚悪性腫瘍学会学術大会プログラム・抄録集, 31回, 179, 179, (一社)日本皮膚悪性腫瘍学会, 2015年07月
日本語 - In-transit metastasisをきたしたprimary mucinous carcinoma of the skinの1例
本間 英里奈; 秦 洋郎; 稲村 有香; 今福 恵輔; 北村 真也; 青柳 哲; 清水 宏
日本皮膚科学会雑誌, 125, 8, 1601, 1601, (公社)日本皮膚科学会, 2015年07月
日本語 - Primary mucinous cell carcinoma of the skinのリンパ節転移に関するPET-CT所見の検討
北村 真也; 秦 洋郎; 稲村 有香; 今福 恵輔; 坂下 智博; 平田 健司; 清水 宏
日本皮膚科学会雑誌, 125, 8, 1601, 1602, (公社)日本皮膚科学会, 2015年07月
日本語 - 著明な形質細胞浸潤を伴ったモルフェアの1例
椎谷 千尋; 岩田 浩明; 今福 恵輔; 山根 尚子; 清水 宏; 伊東 英里
日本皮膚科学会雑誌, 125, 8, 1602, 1602, (公社)日本皮膚科学会, 2015年07月
日本語 - 環状切開とCO2レーザー焼灼を併用し陰茎を温存しえたQueyrat紅色肥厚症の1例
山口 泰之; 秦 洋郎; 今福 恵輔; 北村 真也; 清水 宏
日本皮膚科学会雑誌, 125, 8, 1602, 1602, (公社)日本皮膚科学会, 2015年07月
日本語 - 環状の潰瘍を呈した基底細胞癌の1例
稲村 有香; 秦 洋郎; 今福 恵輔; 北村 真也; 清水 宏
日本皮膚科学会雑誌, 125, 8, 1603, 1603, (公社)日本皮膚科学会, 2015年07月
日本語 - Erythema annulare centrifugum-like mycosis fungoides after unrelated bone marrow transplantation.
Keisuke Imafuku; Yukiko Nomura; Chihiro Nakayama; Riichiro Abe; Tomoyuki Endo; Hiroshi Shimizu
British journal of haematology, 170, 2, 140, 140, 2015年07月, [国際誌]
英語, 研究論文(学術雑誌) - 骨浸潤を伴った手指爪甲下悪性黒色腫の1例
今福 恵輔; 壺井 聡史; 石綿 夏織子; 乙部 さやか; 大原 國章; 吉野 公二
日本皮膚科学会雑誌, 125, 7, 1455, 1455, (公社)日本皮膚科学会, 2015年06月
日本語 - 悪性黒色腫との鑑別を要した爪甲下Bowen病の1例
石綿 夏織子; 今福 恵輔; 壺井 聡史; 乙部 さやか; 大原 國章; 吉野 公二; 堀口 慎一郎
日本皮膚科学会雑誌, 125, 7, 1455, 1455, (公社)日本皮膚科学会, 2015年06月
日本語 - Pazopanib-induced severe acute pancreatitis
Kazumichi Kawakubo; Hiroo Hata; Hiroshi Kawakami; Masaki Kuwatani; Shuhei Kawahata; Kimitoshi Kubo; Keisuke Imafuku; Shinya Kitamura; Naoya Sakamoto
Case Reports in Oncology, 8, 2, 356, 358, S. Karger AG, 2015年05月06日, [査読有り], [国際誌]
英語, 研究論文(学術雑誌) - RAS/MAPK症候群の1例
今福 恵輔; 乃村 俊史; 稲村 有香; 森田 裕介; 本間 英里奈; 山根 尚子; 藤田 靖幸; 阿部 理一郎; 清水 宏
日本皮膚科学会雑誌, 125, 6, 1274, 1274, (公社)日本皮膚科学会, 2015年05月
日本語 - 抗NC16A抗体を有さない軽症の水疱性類天疱瘡の1例
今福 恵輔; 岩田 浩明; 泉 健太郎; 夏賀 健; 氏家 英之; 西江 渉; 清水 宏
日本皮膚科学会雑誌, 125, 4, 915, 915, (公社)日本皮膚科学会, 2015年04月
日本語 - 長期生存が得られた進行期外陰部有棘細胞癌の1例
乙部 さやか; 今福 恵輔; 壺井 聡史; 石綿 夏織子; 大原 國章; 吉野 公二
日本皮膚科学会雑誌, 125, 4, 935, 935, (公社)日本皮膚科学会, 2015年04月
日本語 - Irritated seborrheic keratosisのダーモスコピー所見の検討
北村 真也; 秦 洋郎; 今福 恵輔; 藤田 靖幸; 清水 宏
日本皮膚科学会雑誌, 125, 3, 445, 445, (公社)日本皮膚科学会, 2015年03月
日本語 - RAS/MAPK症候群の1例
今福 恵輔; 乃村 俊史; 稲村 有香; 森田 裕介; 本間 英里奈; 山根 尚子; 藤田 靖幸; 阿部 理一郎; 清水 宏
日本皮膚科学会雑誌, 125, 3, 447, 447, (公社)日本皮膚科学会, 2015年03月
日本語 - High dose FPおよびTS-1療法で、長期寛解を維持している外陰癌肺転移の1例
稲村 有香; 秦 洋郎; 今福 恵輔; 北村 真也; 清水 宏
日本皮膚科学会雑誌, 125, 3, 447, 447, (公社)日本皮膚科学会, 2015年03月
日本語 - Bowen's disease on the palm presents refractory skin erosion without erythematous plaque.
Shinya Kitamura; Hiroaki Iwata; Keisuke Imafuku; Hiroo Hata; Ken Natsuga; Satoru Aoyagi; Hiroshi Shimizu
The Journal of dermatology, 42, 2, 225, 6, 2015年02月, [国際誌]
英語 - 鎖骨内金属インプラントによる皮膚潰瘍の1例
北村 真也; 夏賀 健; 今福 恵輔; 本間 英里奈; 山根 尚子; 青柳 哲; 清水 宏; 松村 哲理
日本皮膚科学会雑誌, 124, 14, 3190, 3190, (公社)日本皮膚科学会, 2014年12月
日本語 - "Sprinkle brightness lesion" appearance in ultrasound B-mode findings of sinusoidal hemangioma.
Shinya Kitamura; Hiroo Hata; Keisuke Imafuku; Wataru Nishie; Hiroshi Shimizu
The Journal of dermatology, 41, 12, 1123, 4, 2014年12月, [国際誌]
英語 - 粘液型脂肪肉腫の1例
今福 恵輔; 秦 洋郎; 森田 裕介; 中山 ちひろ; 北村 真也; 本間 英里奈; 青柳 哲; 安藤 佐土美; 清水 宏
Skin Cancer, 29, 2, 206, 209, (一社)日本皮膚悪性腫瘍学会, 2014年11月
日本語 - 手掌に生じ、HPV16陽性であった色素性ボーエン病の1例
中山 ちひろ; 秦 洋郎; 今福 恵輔; 豊永 愛恋; 清水 宏
日本皮膚科学会雑誌, 124, 11, 2133, 2133, (公社)日本皮膚科学会, 2014年10月
日本語 - Pazopanibは終末期の頭部血管肉腫においても、整容的にQOLを維持しうる
北村 真也; 秦 洋郎; 今福 恵輔; 羽賀 直哉; 濱出 洋平; 本間 英里奈; 清水 宏
日本皮膚科学会雑誌, 124, 11, 2133, 2133, (公社)日本皮膚科学会, 2014年10月
日本語 - In-transit metastasisをきたした進行期エクリン汗孔癌の1例
今福 恵輔; 秦 洋郎; 北村 真也; 清水 宏
日本皮膚科学会雑誌, 124, 11, 2134, 2135, (公社)日本皮膚科学会, 2014年10月
日本語 - 粘液型脂肪肉腫の1例
今福 恵輔; 秦 洋郎; 森田 裕介; 中山 ちひろ; 本間 英里奈; 青柳 哲; 安藤 佐土美; 清水 宏
日本皮膚科学会雑誌, 124, 10, 1939, 1939, (公社)日本皮膚科学会, 2014年09月
日本語 - 悪性黒色腫との鑑別に苦慮した転移性乳癌の1例
北村 真也; 秦 洋郎; 今福 恵輔; 本間 英里奈; 青柳 哲; 清水 宏
日本皮膚科学会雑誌, 124, 10, 1939, 1939, (公社)日本皮膚科学会, 2014年09月
日本語 - 鎖骨内金属インプラントによる皮膚潰瘍の1例
北村 真也; 夏賀 健; 今福 恵輔; 本間 英里奈; 山根 尚子; 青柳 哲; 清水 宏; 松村 哲理
日本皮膚科学会雑誌, 124, 10, 1941, 1941, (公社)日本皮膚科学会, 2014年09月
日本語 - HPV16-related pigmented Bowen's disease on the palm.
Nakayama C; Hata H; Imafuku K; Toyonaga E; Shimizu H
Journal of the European Academy of Dermatology and Venereology : JEADV, 2014年07月
研究論文(学術雑誌) - 臨床的に悪性黒色腫との鑑別に苦慮した、色素沈着を伴った転移性乳癌の1例
北村 真也; 秦 洋郎; 今福 恵輔; 本間 英里奈; 青柳 哲; 清水 宏
日本皮膚悪性腫瘍学会学術大会プログラム・抄録集, 30回, 127, 127, (一社)日本皮膚悪性腫瘍学会, 2014年07月
日本語 - 粘液型脂肪肉腫の1例
今福 恵輔; 安藤 佐土美
日本皮膚悪性腫瘍学会学術大会プログラム・抄録集, 30回, 143, 143, (一社)日本皮膚悪性腫瘍学会, 2014年07月
日本語 - 【内科外来で診るマイナーエマージェンシー 一般実地医家の緊急対処実践ガイド】皮膚科的マイナーエマージェンシー 急性日焼け
今福 恵輔; 青柳 哲
Medical Practice, 31, 臨増, 234, 235, (株)文光堂, 2014年04月
日本語
- 頭部皮膚陥凹から診断に至ったRosai-Dorfman diseaseの1例
樋口 和樹; 今福 恵輔; 小野澤 真弘; 水嶋 慎; 澤谷 亮佑; 氏家 英之, 日本皮膚科学会雑誌, 136, 5, 1113, 1113, 2026年05月
(公社)日本皮膚科学会, 日本語 - ニボルマブ療法を行ったSweat-gland carcinoma with neuroendocrine differentiationの1例
佐藤 聡真; 今福 恵輔; 成瀬 早紀; 田中 有沙; 氏家 英之, 日本皮膚科学会雑誌, 136, 2, 129, 129, 2026年02月
(公社)日本皮膚科学会, 日本語 - Lenvatinib中止後7ヵ月でEccrine Squamous Syringometaplasiaを伴う手足症候群を発症した1例
櫻井 愛美; 三田村 卓; 良川 大晃; 松宮 寛子; 山崎 博之; 黒須 博之; 遠藤 大介; 井平 圭; 金野 陽輔; 武田 真人; 小林 範子; 工藤 正尊; 板本 想太; 今福 恵輔; 渡利 英道, 日本婦人科腫瘍学会学術講演会プログラム・抄録集, 65回, 335, 335, 2023年07月
(公社)日本婦人科腫瘍学会, 日本語 - 若年者の肩部に発生した褐色脂肪腫の1例
小山 逸; 松本 慎二; 角谷 優子; 坂田 祥子; 秋吉 梨江; 西中村 恵輔; 青木 光希子; 古河 祐紀子; 今福 信一; 濱崎 慎, 日本臨床細胞学会九州連合会雑誌, 54, 71, 75, 2023年07月
日本臨床細胞学会-九州連合会, 日本語 - 水疱性類天疱瘡とBullous Rheumatoid Neutrophilic Dermatosisとの鑑別を要したリウマトイド血管炎
田中有沙; 田中有沙; 柳輝希; 今福恵輔; 渥美達也; 氏家英之, 皮膚科の臨床, 65, 10, 2023年 - Retrospective study on the correlation between 18-fluorodeoxyglucose uptake in positron emission tomography–computer tomography and tumour volume, cytological activity as assessed with Ki-67 and GLUT-1 staining in 10 cases of Merkel cell carcinoma
S. Kitamura; T. Yanagi; Y. Inamura-Takashima; K. Imafuku; H. Hata; J. Uehara; Y. Ishida; A. Otsuka; K. Hirata; H. Shimizu, Journal of the European Academy of Dermatology and Venereology, 32, 7, e285, e287, 2018年07月01日
Blackwell Publishing Ltd, 英語, 速報,短報,研究ノート等(学術雑誌) - Baseline neutrophil to lymphocyte ratio combined with serum lactate dehydrogenase level associated with outcome of nivolumab immunotherapy in a Japanese advanced melanoma population.
Fujisawa Y; Yoshino K; Otsuka A; Funakoshi T; Fujimura T; Yamamoto Y; Hata H; Tanaka R; Yamaguchi K; Nonomura Y; Hirai I; Furudate S; Okuhira H; Matsushita S, The British journal of dermatology, 179, 1, 213, 215, 2018年04月
British Journal of Dermatology, その他 - A rare coexistence of pyogenic granuloma and eccrine angiomatous hamartoma
C. Shiiya; H. Hata; K. Imafuku; S. Kitamura; H. Shimizu, Clinical and Experimental Dermatology, 41, 4, 431, 433, 2016年06月01日
Blackwell Publishing Ltd, 英語, 速報,短報,研究ノート等(学術雑誌) - A case of erythroplasia of Queyrat successfully treated with combination carbon dioxide laser vaporization and surgery
Y. Yamaguchi; H. Hata; K. Imafuku; S. Kitamura; H. Shimizu, Journal of the European Academy of Dermatology and Venereology, 30, 3, 497, 498, 2016年03月01日
Blackwell Publishing Ltd, 英語, 速報,短報,研究ノート等(学術雑誌) - 'Millia-like cysts on an erythematous background': Dermoscopic features of keratoacanthoma en plaque
S. Kitamura; H. Hata; K. Imafuku; H. Shimizu, Journal of the European Academy of Dermatology and Venereology, 30, 2, 362, 363, 2016年02月01日
Blackwell Publishing Ltd, 英語, 速報,短報,研究ノート等(学術雑誌) - Giant annular purpuric eruption as a unique clinical manifestation of skin metastasis in apocrine carcinoma
Y. Yamaguchi; S. Kitamura; H. Hata; K. Imafuku; S. Yuzawa; S. Tanaka; H. Shimizu, Journal of the European Academy of Dermatology and Venereology, 30, 6, 1029, 1031, 2016年
Blackwell Publishing Ltd, 英語, 速報,短報,研究ノート等(学術雑誌) - Ultrasound B-mode and elastographic findings of mixed tumour of the skin on the scalp
K. Imafuku; H. Hata; S. Kitamura; H. Iwata; H. Shimizu, Journal of the European Academy of Dermatology and Venereology, 30, 1, 153, 155, 2016年01月01日
速報,短報,研究ノート等(学術雑誌) - Pazopanib can preserve cosmetic quality of life even in end-stage angiosarcoma
S. Kitamura; H. Hata; K. Imafuku; N. Haga; E. Homma; H. Shimizu, Clinical and Experimental Dermatology, 40, 8, 931, 933, 2015年12月01日
Blackwell Publishing Ltd, 英語, 速報,短報,研究ノート等(学術雑誌) - Autoantibodies to parts of type XVII collagen outside of the non-collageneous 16A domain lead to mild bullous pemphigoid due to the non-depletion of autoantigen
H. Iwata; K. Imafuku; K. Izumi; M. Wada; K. Natsuga; H. Ujiie; W. Nishie; H. Shimizu, JOURNAL OF INVESTIGATIVE DERMATOLOGY, 135, S4, S4, 2015年09月
英語, 研究発表ペーパー・要旨(国際会議) - METAL IMPLANT-INDUCED SKIN ULCER MIMICKING SCROFULODERMA
Shinya Kitamura; Ken Natsuga; Keisuke Imafuku; Erina Homma; Naoko Yamane; Satoru Aoyagi; Tetsuri Matsumura; Hiroshi Shimizu, JOURNAL OF DERMATOLOGY, 41, 6, 6, 2014年10月
英語, 研究発表ペーパー・要旨(国際会議)
■ 共同研究・競争的資金等の研究課題
- 炎症性サイトカインが誘導する表皮バリア破綻のミトコンドリア依存機構
2026年08月 - 2028年08月
公益財団法人 武田科学振興財団, 医学研究助成, 北海道大学, 研究代表者, 2026043038 - タイトジャンクションに注目したアトピー性皮膚炎治療リード化合物の探索
科学研究費助成事業
2022年08月31日 - 2023年03月31日
今福 恵輔
本研究の目的はアトピー性皮膚炎の治療薬となり得る小分子化合物を見つけることである。特に皮膚の水分蒸散を防いでいるタイトジャンクション、中でも皮膚に多く発現し、機能的役割をもつクローディン1の発現を促進する化合物を探索している。クローディン1の発現調整に免疫抑制を伴わないため従来のアトピー性皮膚炎の治療と異なる新しい作用機序の薬剤が開発可能となる。また、アトピー性皮膚炎だけでなく、皮膚バリア機能の改善を目指した化粧品開発や、高齢者の皮脂欠乏性湿疹に応用が可能であり、市場におけるインパクトが高い。
10000以上あるライブラリー化合物からレポーターアッセイを用いたスクリーニングを行ったが、開始当初は384wellに手動で細胞を播種していた。しかしながら手技によるばらつきが大きくなってしまったため、再度機械による細胞の播種を行う必要があり、予定より若干の遅れが生じている。本年度はJ-publicraライブラリーからの化合物スクリーニングに終始し、12の化合物まで絞ることができた。更に2次スクリーニングとしてmRNA発現量を確認している。その後は化合物の最適化やアトピー性皮膚炎モデルマウスであるVitD3外用マウスやSPADEマウスを用いた治療実験をおこない、治療前後での組織採取、RNAシーケンスなどを行い、アトピー性皮膚炎で重要であるサイトカインであるIL-4/13経路が抑制されているか、などを検討していく。
日本学術振興会, 研究活動スタート支援, 北海道大学, 22K20915
